Evidence, trial by trial
Every trial in OnCo ranked by a disclosed evidence-strength score, with its primary endpoint drawn as people out of 100 or as median months. The score measures how much and what kind of evidence exists, not how large the benefit is.
How the score is computed
- Phase: 3 → 30 · 2/3 → 22 · 2 → 15 · 1/2 → 8 · 1 → 4 · observational or platform → 10
- Size: 5 × log10(enrolled), capped at 20 (100 people → 10, 1,000 → 15, 10,000 → 20)
- Primary endpoint: overall survival → 20 · time to progression or recurrence → 14 · surrogate (response, pCR, detection) → 8
- Result: positive → 15 · mixed → 6 · ongoing → 0 · negative or withdrawn → −20
- Replication: an independent or consistent confirming study → 10
- A linked product is approved → 5
Products score from their status tier, their best linked trial, and approvals; technologies and targets from their status and best linked product. Full code in src/lib/evidence.ts.
Primary endpoints as pictures
ARASENS · Metastatic hormone-sensitive prostate cancer
Overall survivalprimary
HR 0.68 (0.57–0.8) · p <0.001
Darolutamide + ADT + docetaxel
Median not reached
Placebo + ADT + docetaxel
48.9 mo
Median not reached
SourceCheckMate 649 · First-line HER2-negative advanced gastric/GEJ/oesophageal adenocarcinoma
Overall survival, PD-L1 CPS ≥5primary
HR 0.71 (0.61–0.81)
Nivolumab + chemotherapy
14.4 mo
Chemotherapy
11.1 mo
KEYNOTE-859 · First-line HER2-negative advanced gastric/GEJ adenocarcinoma
Overall survival, all randomisedprimary
HR 0.78 (0.7–0.87)
Pembrolizumab + chemotherapy
12.9 mo
Placebo + chemotherapy
11.5 mo
CASPIAN · First-line extensive-stage SCLC
CheckMate 648 · First-line advanced oesophageal squamous cell carcinoma
Overall survival, PD-L1 ≥1% (nivolumab + chemotherapy)primary
HR 0.54
Nivolumab + chemotherapy
15.4 mo
Chemotherapy
9.1 mo
HIMALAYA · First-line unresectable HCC
Overall survivalprimary
HR 0.78 (0.66–0.92)
STRIDE
16.4 mo
Sorafenib
13.8 mo
KEYNOTE-006 · Advanced melanoma, ≤1 prior systemic therapy
KEYNOTE-024 & KEYNOTE-189 · First-line metastatic NSCLC without EGFR/ALK
KEYNOTE-024: overall survival at 5 years, PD-L1 ≥50%primary
HR 0.62 (0.48–0.81)
Pembrolizumab31.9 of 100
n = 154
Chemotherapy16.3 of 100
n = 151
KEYNOTE-048 · Untreated recurrent or metastatic HNSCC
Overall survival, CPS ≥20, pembrolizumab monotherapyprimary
HR 0.61
Pembrolizumab
14.9 mo
Cetuximab + chemotherapy
10.7 mo
KEYNOTE-355 · First-line metastatic TNBC
Overall survival, PD-L1 CPS ≥10primary
HR 0.73 (0.55–0.95) · p = 0.0185
Pembrolizumab + chemotherapy
23 mo
Placebo + chemotherapy
16.1 mo
KEYNOTE-426 · Untreated advanced clear-cell RCC
Overall survival (final, 5-year)primary
HR 0.84 (0.71–0.99)
Pembrolizumab + axitinib
47.2 mo
Sunitinib
40.8 mo
KEYNOTE-966 · First-line advanced biliary tract cancer
Overall survivalprimary
HR 0.83 (0.72–0.95) · p = 0.0034
Pembrolizumab + GemCis
12.7 mo
Placebo + GemCis
10.9 mo
All trials by evidence strength
| # | Trial | Phase | Result | Primary endpoint | Enrolled | Score |
|---|---|---|---|---|---|---|
| 1 | ARASENS Metastatic hormone-sensitive prostate cancer: ADT + docetaxel + darolutamide vs ADT + docetaxel | Phase 3 | Positive | Overall survival: 48.9 months, HR 0.68 | 1,306 | 96 Strong |
| 2 | CheckMate 649 First-line HER2-negative advanced gastric/GEJ/oesophageal adenocarcinoma: nivolumab + chemotherapy vs chemotherapy | Phase 3 | Positive | Overall survival, PD-L1 CPS ≥5: 14.4 months vs 11.1 months, HR 0.71 | 1,581 | 96 Strong |
| 3 | KEYNOTE-859 First-line HER2-negative advanced gastric/GEJ adenocarcinoma: pembrolizumab + chemotherapy vs placebo + chemotherapy | Phase 3 | Positive | Overall survival, all randomised: 12.9 months vs 11.5 months, HR 0.78 | 1,579 | 96 Strong |
| 4 | CASPIAN First-line extensive-stage SCLC: platinum-etoposide + durvalumab (± tremelimumab) vs platinum-etoposide | Phase 3 | Positive | Overall survival: 13 months vs 10.3 months, HR 0.73 | 805 | 95 Strong |
| 5 | CheckMate 214 Untreated advanced clear-cell RCC: nivolumab + ipilimumab vs sunitinib | Phase 3 | Positive | Overall survival, intermediate/poor risk (8-year follow-up): pending | 1,096 | 95 Strong |
| 6 | CheckMate 648 First-line advanced oesophageal squamous cell carcinoma: nivolumab + chemotherapy, or nivolumab + ipilimumab (chemotherapy-free), vs chemotherapy | Phase 3 | Positive | Overall survival, PD-L1 ≥1% (nivolumab + chemotherapy): 15.4 months vs 9.1 months, HR 0.54 | 970 | 95 Strong |
| 7 | HIMALAYA First-line unresectable HCC: STRIDE (single priming dose tremelimumab + durvalumab) vs sorafenib | Phase 3 | Positive | Overall survival: 16.4 months vs 13.8 months, HR 0.78 | 1,171 | 95 Strong |
| 8 | KEYNOTE-006 Advanced melanoma, ≤1 prior systemic therapy: pembrolizumab (two schedules) vs ipilimumab | Phase 3 | Positive | Overall survival at 10 years: 34% vs 23.6% | 834 | 95 Strong |
| 9 | KEYNOTE-024 & KEYNOTE-189 First-line metastatic NSCLC without EGFR/ALK: pembrolizumab alone (PD-L1 TPS ≥50%, KEYNOTE-024) or pembrolizumab + platinum-pemetrexed (any PD-L1, non-squamous, KEYNOTE-189) | Phase 3 | Positive | KEYNOTE-024: overall survival at 5 years, PD-L1 ≥50%: 31.9% vs 16.3%, HR 0.62 | 921 | 95 Strong |
| 10 | KEYNOTE-048 Untreated recurrent or metastatic HNSCC: pembrolizumab alone, pembrolizumab + platinum/5-FU, or cetuximab + platinum/5-FU (EXTREME) | Phase 3 | Positive | Overall survival, CPS ≥20, pembrolizumab monotherapy: 14.9 months vs 10.7 months, HR 0.61 | 882 | 95 Strong |
| 11 | KEYNOTE-355 First-line metastatic TNBC: pembrolizumab + chemotherapy vs chemotherapy | Phase 3 | Positive | Overall survival, PD-L1 CPS ≥10: 23 months vs 16.1 months, HR 0.73 | 847 | 95 Strong |
| 12 | KEYNOTE-426 Untreated advanced clear-cell RCC: pembrolizumab + axitinib vs sunitinib | Phase 3 | Positive | Overall survival (final, 5-year): 47.2 months vs 40.8 months, HR 0.84 | 861 | 95 Strong |
| 13 | KEYNOTE-966 First-line advanced biliary tract cancer: gemcitabine-cisplatin + pembrolizumab vs + placebo | Phase 3 | Positive | Overall survival: 12.7 months vs 10.9 months, HR 0.83 | 1,069 | 95 Strong |
| 14 | LATITUDE High-risk de novo metastatic hormone-sensitive prostate cancer: ADT + abiraterone vs ADT | Phase 3 | Positive | Overall survival: 53.3 months vs 36.5 months, HR 0.66 | 1,199 | 95 Strong |
| 15 | PARADIGM First-line RAS wild-type metastatic colorectal cancer: panitumumab + mFOLFOX6 vs bevacizumab + mFOLFOX6 | Phase 3 | Positive | Overall survival, left-sided: 37.9 months vs 34.3 months, HR 0.82 | 823 | 95 Strong |
| 16 | PEACE-1 De novo metastatic hormone-sensitive prostate cancer: ADT + docetaxel ± abiraterone ± prostate radiotherapy (2×2 factorial) | Phase 3 | Positive | Overall survival, abiraterone vs no abiraterone (with ADT + docetaxel): 66 months vs 52 months, HR 0.75 | 1,173 | 95 Strong |
| 17 | VISION PSMA+ metastatic castration-resistant prostate cancer after ARPI and taxane: 177Lu-PSMA-617 + SOC vs SOC | Phase 3 | Positive | Overall survival: 15.3 months vs 11.3 months, HR 0.62 | 831 | 95 Strong |
| 18 | ASTRUM-005 First-line ES-SCLC: serplulimab + carboplatin-etoposide vs placebo + carboplatin-etoposide | Phase 3 | Positive | Overall survival: 15.4 months vs 10.9 months, HR 0.63 | 585 | 94 Strong |
| 19 | CHAARTED (E3805) Metastatic hormone-sensitive prostate cancer: ADT + docetaxel vs ADT | Phase 3 | Positive | Overall survival: 57.6 months vs 44 months, HR 0.61 | 790 | 94 Strong |
| 20 | DeLLphi-304 Second-line small-cell lung cancer: tarlatamab vs chemotherapy | Phase 3 | Positive | Overall survival: 13.6 months vs 8.3 months, HR 0.6 | 509 | 94 Strong |
| 21 | EORTC 26981 / NCIC CE.3 (Stupp trial) Newly diagnosed glioblastoma: radiotherapy + concurrent and adjuvant temozolomide vs radiotherapy alone | Phase 3 | Positive | Overall survival: 14.6 months vs 12.1 months, HR 0.63 | 573 | 94 Strong |
| 22 | ESCORT-1st First-line advanced oesophageal squamous cell carcinoma (China): camrelizumab + paclitaxel/cisplatin vs placebo + chemotherapy | Phase 3 | Positive | Overall survival: 15.3 months vs 12 months, HR 0.7 | 596 | 94 Strong |
| 23 | FRESCO-2 Refractory metastatic colorectal cancer after all standard therapies: fruquintinib vs placebo | Phase 3 | Positive | Overall survival: 7.4 months vs 4.8 months, HR 0.66 | 691 | 94 Strong |
| 24 | HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab) Adjuvant HER2+ early breast cancer: one year of trastuzumab with or after chemotherapy vs chemotherapy alone | Phase 3 | Positive | Disease-free survival (B-31/N9831): pending | 9,000 | 94 Strong |
| 25 | JAVELIN Bladder 100 Advanced urothelial cancer without progression after 4-6 cycles of platinum chemotherapy: avelumab maintenance + best supportive care vs BSC | Phase 3 | Positive | Overall survival: 21.4 months vs 14.3 months, HR 0.69 | 700 | 94 Strong |
| 26 | KEYNOTE-590 First-line advanced oesophageal cancer (squamous and adenocarcinoma) and Siewert I GEJ: pembrolizumab + cisplatin/5-FU vs chemotherapy | Phase 3 | Positive | Overall survival, all patients: 12.4 months vs 9.8 months, HR 0.73 | 749 | 94 Strong |
| 27 | KEYNOTE-826 Persistent, recurrent, or metastatic cervical cancer, first line: pembrolizumab + platinum-paclitaxel ± bevacizumab vs placebo + chemotherapy ± bevacizumab | Phase 3 | Positive | Overall survival (all comers): 26.4 months vs 16.8 months, HR 0.63 | 617 | 94 Strong |
| 28 | NAPOLI 3 First-line metastatic PDAC: NALIRIFOX vs gemcitabine + nab-paclitaxel | Phase 3 | Positive | Overall survival: 11.1 months vs 9.2 months, HR 0.83 | 770 | 94 Strong |
| 29 | QuANTUM-First Newly diagnosed FLT3-ITD AML, age 18-75: quizartinib vs placebo with 7+3, consolidation, and up to 3 years of maintenance | Phase 3 | Positive | Overall survival (median): 31.9 months vs 15.1 months, HR 0.776 | 539 | 94 Strong |
| 30 | RAINBOW Second-line advanced gastric/GEJ cancer: ramucirumab + paclitaxel vs paclitaxel | Phase 3 | Positive | Overall survival: 9.6 months vs 7.4 months, HR 0.81 | 665 | 94 Strong |
| 31 | RATIFY (CALGB 10603) Newly diagnosed FLT3-mutated AML, age 18-59: midostaurin vs placebo added to 7+3, consolidation, and one year of maintenance | Phase 3 | Positive | Overall survival (median): 74.7 months vs 25.6 months, HR 0.78 | 717 | 94 Strong |
| 32 | RATIONALE-306 First-line advanced oesophageal squamous cell carcinoma: tislelizumab + platinum chemotherapy vs placebo + chemotherapy | Phase 3 | Positive | Overall survival, all patients: 17.2 months vs 10.6 months, HR 0.66 | 649 | 94 Strong |
| 33 | SHARP Advanced HCC, Child-Pugh A, no prior systemic therapy: sorafenib vs placebo | Phase 3 | Positive | Overall survival: 10.7 months vs 7.9 months, HR 0.69 | 602 | 94 Strong |
| 34 | ToGA First-line HER2-positive advanced gastric/GEJ adenocarcinoma: trastuzumab + cisplatin/fluoropyrimidine vs chemotherapy | Phase 3 | Positive | Overall survival: 13.8 months vs 11.1 months, HR 0.74 | 594 | 94 Strong |
| 35 | TOPAZ-1 First-line advanced biliary tract cancer: gemcitabine-cisplatin + durvalumab vs + placebo | Phase 3 | Positive | Overall survival (updated): 12.9 months vs 11.3 months, HR 0.76 | 685 | 94 Strong |
| 36 | ABC-02 Locally advanced or metastatic biliary tract cancer: gemcitabine + cisplatin vs gemcitabine | Phase 3 | Positive | Overall survival: 11.7 months vs 8.1 months, HR 0.64 | 410 | 93 Strong |
| 37 | ADMIRAL Relapsed or refractory FLT3-mutated AML: gilteritinib monotherapy vs salvage chemotherapy | Phase 3 | Positive | Overall survival (median): 9.3 months vs 5.6 months, HR 0.64 | 371 | 93 Strong |
| 38 | CheckMate 141 Platinum-refractory recurrent or metastatic HNSCC: nivolumab vs investigator's choice (methotrexate, docetaxel, or cetuximab) | Phase 3 | Positive | Overall survival: 7.5 months vs 5.1 months, HR 0.7 | 361 | 93 Strong |
| 39 | CROSS Resectable oesophageal or junctional cancer (squamous and adenocarcinoma): weekly carboplatin/paclitaxel + 41.4 Gy radiation then surgery vs surgery alone | Phase 3 | Positive | Overall survival: 49.4 months vs 24 months, HR 0.68 | 366 | 93 Strong |
| 40 | DESTINY-Gastric04 Second-line HER2-positive gastric/GEJ cancer after trastuzumab: T-DXd vs ramucirumab + paclitaxel | Phase 3 | Positive | Overall survival: 14.7 months vs 11.4 months, HR 0.7 | 494 | 93 Strong |
| 41 | ECOG-ACRIN E1910 Newly diagnosed Ph-negative B-ALL, age 30-70, in MRD-negative remission after induction: blinatumomab added to consolidation chemotherapy vs chemotherapy alone | Phase 3 | Positive | Overall survival at 3 years (MRD-negative cohort): 85% vs 68%, HR 0.41 | 488 | 93 Strong |
| 42 | IMbrave150 First-line unresectable HCC: atezolizumab + bevacizumab vs sorafenib | Phase 3 | Positive | Overall survival (updated): 19.2 months vs 13.4 months, HR 0.66 | 501 | 93 Strong |
| 43 | IMCgp100-202 Untreated HLA-A*02:01-positive metastatic uveal melanoma: tebentafusp vs investigator's choice (pembrolizumab, ipilimumab, or dacarbazine) | Phase 3 | Positive | Overall survival: 21.7 months vs 16 months, HR 0.51 | 378 | 93 Strong |
| 44 | IMpower133 First-line extensive-stage SCLC: carboplatin-etoposide + atezolizumab vs carboplatin-etoposide + placebo | Phase 3 | Positive | Overall survival: 12.3 months vs 10.3 months, HR 0.7 | 403 | 93 Strong |
| 45 | IND.227 / KEYNOTE-483 Unresectable pleural mesothelioma, first line: pembrolizumab + platinum-pemetrexed vs platinum-pemetrexed | Phase 3 | Positive | Overall survival: 17.3 months vs 16.1 months, HR 0.79 | 440 | 93 Strong |
| 46 | monarchE Adjuvant abemaciclib 2 years + endocrine therapy in high-risk node-positive HR+/HER2- breast cancer | Phase 3 | Positive | Invasive disease-free survival at 2 years: 92.2% vs 88.7%, HR 0.75 | 5,637 | 93 Strong |
| 47 | NATALEE Adjuvant ribociclib 3 years + endocrine therapy in stage II-III HR+/HER2- breast cancer | Phase 3 | Positive | Invasive disease-free survival at 3 years: 90.4% vs 87.1%, HR 0.75 | 5,101 | 93 Strong |
| 48 | SOFT & TEXT Premenopausal HR+ early breast cancer: ovarian function suppression + exemestane vs + tamoxifen vs tamoxifen alone | Phase 3 | Positive | 12-year disease-free survival (TEXT+SOFT): 80.5% vs 75.9%, HR 0.79 | 5,738 | 93 Strong |
| 49 | SUNLIGHT Refractory metastatic colorectal cancer: trifluridine/tipiracil + bevacizumab vs trifluridine/tipiracil | Phase 3 | Positive | Overall survival: 10.8 months vs 7.5 months, HR 0.61 | 492 | 93 Strong |
| 50 | TOWER Relapsed or refractory Ph-negative B-ALL, adults: blinatumomab vs standard salvage chemotherapy | Phase 3 | Positive | Overall survival (median): 7.7 months vs 4 months, HR 0.71 | 405 | 93 Strong |
| 51 | VIALE-A Newly diagnosed AML unfit for intensive chemotherapy: venetoclax + azacitidine vs placebo + azacitidine | Phase 3 | Positive | Overall survival (median): 14.7 months vs 9.6 months, HR 0.66 | 431 | 93 Strong |
| 52 | APHINITY Adjuvant HER2+ early breast cancer: pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy | Phase 3 | Positive | 8-year invasive disease-free survival: 88.4% vs 85.8%, HR 0.78 | 4,805 | 92 Strong |
| 53 | DREAMseq (ECOG-ACRIN EA6134) Untreated BRAF V600 metastatic melanoma: nivolumab + ipilimumab then dabrafenib + trametinib at progression, vs the reverse sequence | Phase 3 | Positive | Overall survival at 2 years: 71.8% vs 51.5% | 265 | 92 Strong |
| 54 | PERSEPHONE Adjuvant HER2+ early breast cancer: 6 vs 12 months of trastuzumab | Phase 3 | Positive | 4-year disease-free survival: 89.4% vs 89.8%, HR 1.07 | 4,088 | 92 Strong |
| 55 | THOR Advanced urothelial cancer with FGFR3/2 alterations after chemotherapy and a checkpoint inhibitor: erdafitinib vs chemotherapy (cohort 1) | Phase 3 | Positive | Overall survival (cohort 1): 12.1 months vs 7.8 months, HR 0.64 | 266 | 92 Strong |
| 56 | COG AALL1731 Newly diagnosed standard-risk B-ALL in children: two cycles of blinatumomab added to chemotherapy vs chemotherapy alone | Phase 3 | Positive | Disease-free survival at 3 years: 96% vs 87.9%, HR 0.39 | 1,440 | 90 Strong |
| 57 | DESTINY-Breast05 High-risk HER2+ early breast cancer with residual invasive disease after neoadjuvant therapy: T-DXd vs T-DM1 | Phase 3 | Positive | 3-year invasive disease-free survival: 92.4% vs 83.7%, HR 0.47 | 1,635 | 90 Strong |
| 58 | KATHERINE HER2+ early breast cancer with residual invasive disease after neoadjuvant therapy: T-DM1 vs trastuzumab for 14 cycles | Phase 3 | Positive | 3-year invasive disease-free survival: 88.3% vs 77%, HR 0.5 | 1,486 | 90 Strong |
| 59 | AMPLIFY Fit, previously untreated CLL without del(17p)/TP53: fixed-duration acalabrutinib + venetoclax (AV) or + obinutuzumab (AVO) vs FCR/BR chemoimmunotherapy | Phase 3 | Positive | Progression-free survival at 3 years: 76.5% vs 83.1% vs 66.5% | 867 | 89 Strong |
| 60 | ARCHES Metastatic hormone-sensitive prostate cancer: ADT + enzalutamide vs ADT | Phase 3 | Positive | Radiographic progression-free survival: 19 months, HR 0.39 | 1,150 | 89 Strong |
| 61 | CheckMate 067 Untreated advanced melanoma: nivolumab + ipilimumab vs nivolumab vs ipilimumab | Phase 3 | Positive | Progression-free survival (co-primary): 11.5 months vs 6.9 months vs 2.9 months, HR 0.42 | 945 | 89 Strong |
| 62 | CheckMate 8HW MSI-H/dMMR metastatic colorectal cancer, all lines: nivolumab + ipilimumab vs nivolumab vs chemotherapy | Phase 3 | Positive | Progression-free survival, first line: 54.1 months vs 5.9 months, HR 0.21 | 839 | 89 Strong |
| 63 | CLEAR (KEYNOTE-581) Untreated advanced clear-cell RCC: lenvatinib + pembrolizumab vs sunitinib (and lenvatinib + everolimus arm) | Phase 3 | Positive | Progression-free survival: 23.9 months vs 9.2 months, HR 0.39 | 1,069 | 89 Strong |
| 64 | CLEOPATRA First-line HER2+ metastatic breast cancer: pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel | Phase 3 | Positive | Progression-free survival: 18.7 months vs 12.4 months, HR 0.68 | 808 | 89 Strong |
| 65 | DESTINY-Breast06 HR+ HER2-low/ultralow breast cancer after endocrine therapy, chemotherapy-naive: T-DXd vs chemotherapy | Phase 3 | Positive | Progression-free survival, HER2-low (BICR): 13.2 months vs 8.1 months, HR 0.62 | 866 | 89 Strong |
| 66 | EMBER-3 ER+/HER2- advanced breast cancer after ≥1 endocrine line: imlunestrant vs standard endocrine therapy, and imlunestrant + abemaciclib vs imlunestrant | Phase 3 | Positive | Progression-free survival, ESR1-mutant (imlunestrant vs standard ET): 5.5 months vs 3.8 months, HR 0.62 | 874 | 89 Strong |
| 67 | EV-302 / KEYNOTE-A39 First-line advanced urothelial cancer: enfortumab vedotin + pembrolizumab vs platinum chemotherapy | Phase 3 | Positive | Progression-free survival (BICR): 12.5 months vs 6.3 months, HR 0.45 | 886 | 89 Strong |
| 68 | HERIZON-GEA-01 First-line HER2-positive advanced gastro-oesophageal adenocarcinoma: zanidatamab + chemotherapy ± tislelizumab vs trastuzumab + chemotherapy | Phase 3 | Positive | Progression-free survival: 12.4 months vs 12.4 months vs 8.1 months | 914 | 89 Strong |
| 69 | INTerpath-001 (V940-001) Adjuvant resected stage IIB-IV melanoma: intismeran autogene + pembrolizumab vs pembrolizumab | Phase 3 | Positive | Recurrence-free survival: Met; hazard ratio and medians not yet disclosed (topline 19 August 2026). | 1,137 | 89 Strong |
| 70 | KEYNOTE-671 Resectable stage II-IIIB NSCLC: neoadjuvant pembrolizumab + chemotherapy then adjuvant pembrolizumab vs placebo | Phase 3 | Positive | Event-free survival: 47.2 months vs 18.3 months, HR 0.59 | 797 | 89 Strong |
| 71 | KEYNOTE-A18 / ENGOT-cx11 / GOG-3047 Newly diagnosed high-risk locally advanced cervical cancer (FIGO 2014 IB2-IIB node-positive or III-IVA): pembrolizumab + cisplatin chemoradiation + brachytherapy, then pembrolizumab, vs chemoradiation | Phase 3 | Positive | Progression-free survival at 24 months: 68% vs 57%, HR 0.7 | 1,060 | 89 Strong |
| 72 | MATTERHORN Resectable stage II-IVA gastric/GEJ adenocarcinoma: perioperative FLOT + durvalumab vs FLOT + placebo | Phase 3 | Positive | Event-free survival: pending | 948 | 89 Strong |
| 73 | NIAGARA Cisplatin-eligible muscle-invasive bladder cancer: neoadjuvant durvalumab + gemcitabine-cisplatin, cystectomy, adjuvant durvalumab vs neoadjuvant chemotherapy and cystectomy | Phase 3 | Positive | Event-free survival: 46.1 months, HR 0.68 | 1,063 | 89 Strong |
| 74 | POLARIX Untreated DLBCL, IPI 2-5, age 18-80: Pola-R-CHP vs R-CHOP | Phase 3 | Positive | Progression-free survival at 2 years: 76.7% vs 70.2%, HR 0.73 | 879 | 89 Strong |
| 75 | PORTEC-3 High-risk early or stage III endometrial cancer after surgery: chemoradiation + 4 cycles chemotherapy vs pelvic radiotherapy alone | Phase 3 | Positive | Overall survival at 5 years: 81.4% vs 76.1%, HR 0.7 | 660 | 89 Strong |
| 76 | POTOMAC BCG-naive high-risk non-muscle-invasive bladder cancer: durvalumab + BCG (induction and maintenance) vs BCG | Phase 3 | Positive | Disease-free survival: pending | 1,018 | 89 Strong |
| 77 | PROpel First-line mCRPC, all-comers: abiraterone + olaparib vs abiraterone + placebo | Phase 3 | Positive | Radiographic progression-free survival (investigator), all comers: 24.8 months vs 16.6 months, HR 0.66 | 796 | 89 Strong |
| 78 | PSMAddition PSMA-positive metastatic hormone-sensitive prostate cancer: 177Lu-PSMA-617 + ADT + ARPI vs ADT + ARPI | Phase 3 | Positive | Radiographic progression-free survival: Updated HR 0.67; OS HR 0.80, immature | 1,144 | 89 Strong |
| 79 | SWOG S1826 Untreated stage III-IV classical Hodgkin lymphoma, age ≥12: nivolumab + AVD vs brentuximab vedotin + AVD | Phase 3 | Positive | Progression-free survival at 2 years: 92% vs 83%, HR 0.45 | 994 | 89 Strong |
| 80 | TAILORx HR+/HER2-, node-negative early breast cancer with Oncotype DX recurrence score 11-25: endocrine therapy alone vs chemo-endocrine therapy | Phase 3 | Positive | Invasive disease-free survival at 9 years (RS 11-25): 83.3% vs 84.3%, HR 1.08 | 10,273 | 89 Strong |
| 81 | TALAPRO-2 First-line mCRPC: enzalutamide + talazoparib vs enzalutamide + placebo (all-comers and HRR-mutant cohorts) | Phase 3 | Positive | Radiographic progression-free survival, all comers: 21.9 months, HR 0.63 | 805 | 89 Strong |
| 82 | ALPINE Relapsed or refractory CLL/SLL: zanubrutinib vs ibrutinib | Phase 3 | Positive | Progression-free survival: pending | 652 | 88 Strong |
| 83 | ASCENT Pretreated metastatic TNBC: sacituzumab govitecan vs chemotherapy | Phase 3 | Positive | Progression-free survival (patients without brain metastases): 5.6 months vs 1.7 months, HR 0.41 | 529 | 88 Strong |
| 84 | ASCENT-03 First-line metastatic TNBC, not candidates for PD-1 inhibitors: sacituzumab govitecan vs chemotherapy | Phase 3 | Positive | Progression-free survival (BICR): 9.7 months vs 6.9 months, HR 0.62 | 558 | 88 Strong |
| 85 | ATOMIC (Alliance A021502) Resected stage III dMMR colon cancer: adjuvant FOLFOX + atezolizumab (12 months) vs FOLFOX | Phase 3 | Positive | Disease-free survival at 3 years: 86.4 percent vs 76.6 percent, HR 0.5 | 712 | 88 Strong |
| 86 | CAPItello-291 HR+/HER2- advanced breast cancer after aromatase inhibitor (± CDK4/6): capivasertib + fulvestrant vs placebo + fulvestrant | Phase 3 | Positive | Progression-free survival (overall): 7.2 months vs 3.6 months, HR 0.6 | 708 | 88 Strong |
| 87 | CheckMate 274 High-risk muscle-invasive urothelial carcinoma after radical surgery: adjuvant nivolumab 1 year vs placebo | Phase 3 | Positive | Disease-free survival: 22 months vs 10.9 months, HR 0.7 | 709 | 88 Strong |
| 88 | CheckMate 9ER Untreated advanced clear-cell RCC: nivolumab + cabozantinib vs sunitinib | Phase 3 | Positive | Progression-free survival: 16.6 months vs 8.3 months, HR 0.51 | 651 | 88 Strong |
| 89 | COLUMBUS Advanced BRAF V600 melanoma: encorafenib + binimetinib vs vemurafenib vs encorafenib | Phase 3 | Positive | Progression-free survival: 14.9 months vs 7.3 months, HR 0.54 | 577 | 88 Strong |
| 90 | DESKTOP III / ENGOT-ov20 First platinum-sensitive relapse with a positive AGO score: secondary cytoreductive surgery + chemotherapy vs chemotherapy alone | Phase 3 | Positive | Overall survival: 53.7 months vs 46 months, HR 0.75 | 407 | 88 Strong |
| 91 | DESTINY-Breast03 HER2+ metastatic breast cancer after trastuzumab and taxane: T-DXd vs T-DM1 | Phase 3 | Positive | Progression-free survival (BICR): 28.8 months vs 6.8 months, HR 0.33 | 524 | 88 Strong |
| 92 | DESTINY-Breast04 HER2-low metastatic breast cancer after chemotherapy: T-DXd vs chemotherapy | Phase 3 | Positive | Progression-free survival, HR+ cohort (BICR): 10.1 months vs 5.4 months, HR 0.51 | 557 | 88 Strong |
| 93 | ELEVATE-TN Previously untreated CLL, age ≥65 or with comorbidities: acalabrutinib ± obinutuzumab vs chlorambucil + obinutuzumab | Phase 3 | Positive | Progression-free survival (median, 6-year follow-up): 27.8 months | 535 | 88 Strong |
| 94 | EXTREME Untreated recurrent or metastatic HNSCC: cetuximab + platinum/5-FU vs platinum/5-FU | Phase 3 | Positive | Overall survival: 10.1 months vs 7.4 months, HR 0.8 | 442 | 88 Strong |
| 95 | FLAURA2 First-line EGFR-mutant NSCLC: osimertinib + chemotherapy vs osimertinib | Phase 3 | Positive | Progression-free survival (investigator): 25.5 months vs 16.7 months, HR 0.62 | 557 | 88 Strong |
| 96 | HER2CLIMB HER2+ metastatic breast cancer after trastuzumab, pertuzumab, and T-DM1, including active brain metastases: tucatinib + trastuzumab + capecitabine vs placebo + trastuzumab + capecitabine | Phase 3 | Positive | Progression-free survival: 7.8 months vs 5.6 months, HR 0.54 | 612 | 88 Strong |
| 97 | HER2CLIMB-05 First-line HER2+ metastatic breast cancer after induction with taxane + trastuzumab + pertuzumab: maintenance tucatinib + HP vs placebo + HP | Phase 3 | Positive | Progression-free survival: 24.9 months vs 16.3 months, HR 0.641 | 654 | 88 Strong |
| 98 | IMvigor011 Muscle-invasive bladder cancer after cystectomy, ctDNA-positive (Signatera): atezolizumab vs placebo | Phase 3 | Positive | Disease-free survival (ctDNA-positive, randomised): 9.9 months vs 4.8 months, HR 0.64 | 761 | 88 Strong |
| 99 | LITESPARK-005 Advanced clear-cell RCC after PD-1/PD-L1 and VEGF-TKI: belzutifan vs everolimus | Phase 3 | Positive | Progression-free survival: pending | 746 | 88 Strong |
| 100 | MONALEESA-2 First-line postmenopausal HR+/HER2- advanced breast cancer: ribociclib + letrozole vs placebo + letrozole | Phase 3 | Positive | Progression-free survival: 25.3 months vs 16 months, HR 0.57 | 668 | 88 Strong |
| 101 | PACIFIC Unresectable stage III NSCLC without progression after chemoradiation: durvalumab 1 year vs placebo | Phase 3 | Positive | Progression-free survival (BICR): 16.8 months vs 5.6 months, HR 0.52 | 713 | 88 Strong |
| 102 | PERSEUS Newly diagnosed transplant-eligible myeloma: Dara-VRd induction/consolidation + DR maintenance vs VRd + R | Phase 3 | Positive | Progression-free survival at 48 months: 84.3% vs 67.7%, HR 0.42 | 709 | 88 Strong |
| 103 | RxPONDER (SWOG S1007) HR+/HER2- breast cancer with 1-3 positive nodes and recurrence score ≤25: endocrine therapy alone vs chemo-endocrine therapy | Phase 3 | Positive | 5-year iDFS, postmenopausal: 91.9% vs 91.3%, HR 1.02 | 5,083 | 88 Strong |
| 104 | SEQUOIA Previously untreated CLL/SLL unsuitable for FCR: zanubrutinib vs bendamustine-rituximab (cohort 1); zanubrutinib in del(17p) (arm C); zanubrutinib + venetoclax (arm D) | Phase 3 | Positive | Progression-free survival (cohort 1): pending | 590 | 88 Strong |
| 105 | SOLAR-1 HR+/HER2- advanced breast cancer after aromatase inhibitor: alpelisib + fulvestrant vs placebo + fulvestrant, by PIK3CA status | Phase 3 | Positive | Progression-free survival (PIK3CA-mutant): 11 months vs 5.7 months, HR 0.65 | 572 | 88 Strong |
| 106 | TROPiCS-02 HR+/HER2- metastatic breast cancer after endocrine therapy, CDK4/6, and 2-4 chemotherapies: sacituzumab govitecan vs chemotherapy | Phase 3 | Positive | Progression-free survival: 5.5 months vs 4 months, HR 0.66 | 543 | 88 Strong |
| 107 | TROPION-Breast02 First-line metastatic TNBC, not candidates for PD-1/PD-L1: Dato-DXd vs chemotherapy | Phase 3 | Positive | Progression-free survival (BICR): 10.8 months vs 5.6 months, HR 0.57 | 644 | 88 Strong |
| 108 | ASCENT-04 / KEYNOTE-D19 First-line PD-L1+ (CPS ≥10) metastatic TNBC: sacituzumab govitecan + pembrolizumab vs chemotherapy + pembrolizumab | Phase 3 | Positive | Progression-free survival (BICR): 11.2 months vs 7.8 months, HR 0.65 | 443 | 87 Strong |
| 109 | CARTITUDE-4 Lenalidomide-refractory myeloma after 1-3 prior lines: cilta-cel vs Pom-Vd or Dara-Pd | Phase 3 | Positive | Progression-free survival: pending | 419 | 87 Strong |
| 110 | CLL14 Previously untreated CLL with coexisting conditions: 12 months of venetoclax + obinutuzumab vs chlorambucil + obinutuzumab | Phase 3 | Positive | Progression-free survival (median): 76.2 months vs 36.4 months, HR 0.4 | 432 | 87 Strong |
| 111 | CodeBreaK 200 Previously treated KRAS G12C NSCLC: sotorasib vs docetaxel | Phase 3 | Positive | Progression-free survival (BICR): 5.6 months vs 4.5 months, HR 0.66 | 345 | 87 Strong |
| 112 | DREAMM-7 Relapsed myeloma after ≥1 line: belantamab-Vd vs Dara-Vd | Phase 3 | Positive | Progression-free survival (median): 36.6 months vs 13.4 months, HR 0.41 | 494 | 87 Strong |
| 113 | EMERALD ER+/HER2- advanced breast cancer after 1-2 endocrine lines including a CDK4/6 inhibitor: elacestrant vs standard endocrine therapy | Phase 3 | Positive | Progression-free survival (ESR1-mutant): 3.8 months vs 1.9 months, HR 0.55 | 478 | 87 Strong |
| 114 | EV-303 / KEYNOTE-905 Cisplatin-ineligible MIBC: perioperative enfortumab vedotin + pembrolizumab with cystectomy vs cystectomy alone | Phase 3 | Positive | Event-free survival: pending | 344 | 87 Strong |
| 115 | evERA ER+/HER2- advanced breast cancer after CDK4/6 inhibitor: giredestrant + everolimus vs standard endocrine therapy + everolimus | Phase 3 | Positive | Progression-free survival (ITT): 8.77 months vs 5.49 months, HR 0.56 | 320 | 87 Strong |
| 116 | HORIZON-Breast01 HER2+ metastatic breast cancer after trastuzumab and taxane (China): trastuzumab rezetecan (SHR-A1811) vs pyrotinib + capecitabine | Phase 3 | Positive | Progression-free survival (BICR): 30.6 months vs 8.3 months, HR 0.22 | 366 | 87 Strong |
| 117 | INTERLACE Locally advanced cervical cancer: 6 weeks of induction carboplatin-paclitaxel before chemoradiation vs chemoradiation alone | Phase 3 | Positive | Progression-free survival at 5 years: 72% vs 64%, HR 0.65 | 500 | 87 Strong |
| 118 | KRYSTAL-12 Previously treated KRAS G12C NSCLC: adagrasib vs docetaxel | Phase 3 | Positive | Progression-free survival (BICR): 5.5 months vs 3.8 months, HR 0.58 | 453 | 87 Strong |
| 119 | lidERA Adjuvant ER+/HER2- early breast cancer (medium-high risk): giredestrant vs standard endocrine therapy for 5 years | Phase 3 | Positive | Invasive disease-free survival: 30% reduction in iDFS events vs standard ET | 4,200 | 87 Strong |
| 120 | MONARCH 3 First-line postmenopausal HR+/HER2- advanced breast cancer: abemaciclib + NSAI vs placebo + NSAI | Phase 3 | Positive | Progression-free survival: 28.2 months vs 14.8 months, HR 0.54 | 493 | 87 Strong |
| 121 | NADINA Resectable macroscopic stage III melanoma: two cycles neoadjuvant ipilimumab + nivolumab then surgery (adjuvant only if incomplete response) vs surgery then 12 cycles adjuvant nivolumab | Phase 3 | Positive | Event-free survival at 12 months: 83.7% vs 57.2%, HR 0.32 | 423 | 87 Strong |
| 122 | OVHIPEC-1 Stage III ovarian cancer at interval cytoreductive surgery after neoadjuvant chemotherapy: HIPEC with cisplatin vs surgery alone | Phase 3 | Positive | Overall survival: 45.7 months vs 33.9 months, HR 0.67 | 245 | 87 Strong |
| 123 | postMONARCH HR+/HER2- advanced breast cancer after progression on CDK4/6 + endocrine therapy: abemaciclib + fulvestrant vs placebo + fulvestrant | Phase 3 | Positive | Progression-free survival: 6 months vs 5.3 months, HR 0.73 | 368 | 87 Strong |
| 124 | PRODIGE 24 / CCTG PA6 Adjuvant therapy after resection of PDAC: mFOLFIRINOX vs gemcitabine | Phase 3 | Positive | Disease-free survival: 21.6 months vs 12.8 months, HR 0.58 | 493 | 87 Strong |
| 125 | PROfound mCRPC with HRR gene alterations after ARPI: olaparib vs enzalutamide/abiraterone switch | Phase 3 | Positive | Radiographic progression-free survival, cohort A (BRCA1/2, ATM): 7.4 months vs 3.6 months, HR 0.34 | 387 | 87 Strong |
| 126 | PSMAfore PSMA+ mCRPC after one ARPI, taxane-naive: 177Lu-PSMA-617 vs ARPI switch | Phase 3 | Positive | Radiographic progression-free survival: 12 months vs 5.6 months, HR 0.41 | 468 | 87 Strong |
| 127 | RESONATE Relapsed or refractory CLL/SLL: ibrutinib vs ofatumumab | Phase 3 | Positive | Progression-free survival: pending | 391 | 87 Strong |
| 128 | RUBY / ENGOT-EN6 / GOG-3031 Primary advanced (stage III-IV) or first recurrent endometrial cancer: dostarlimab + carboplatin-paclitaxel, then dostarlimab up to 3 years, vs chemotherapy | Phase 3 | Positive | Progression-free survival at 24 months (dMMR/MSI-H): 61.4% vs 15.7%, HR 0.28 | 494 | 87 Strong |
| 129 | SANO Oesophageal cancer with clinical complete response after CROSS chemoradiation: active surveillance (surgery only on regrowth) vs standard surgery | Phase 3 | Positive | Overall survival at 2 years (non-inferiority): pending | 274 | 87 Strong |
| 130 | SOLO-1 Newly diagnosed advanced BRCA-mutated ovarian cancer in response to platinum chemotherapy: olaparib maintenance for 2 years vs placebo | Phase 3 | Positive | Progression-free survival: pending | 391 | 87 Strong |
| 131 | ZUMA-7 Large B-cell lymphoma refractory or relapsed within 12 months of frontline therapy: axi-cel vs salvage chemotherapy + autologous transplant | Phase 3 | Positive | Event-free survival (median): 8.3 months vs 2 months, HR 0.4 | 359 | 87 Strong |
| 132 | ALFA-0701 Newly diagnosed de novo AML, age 50-70: fractionated gemtuzumab ozogamicin added to 7+3 vs 7+3 alone | Phase 3 | Positive | Event-free survival (median): 17.3 months vs 9.5 months, HR 0.56 | 271 | 86 Strong |
| 133 | ALINA Adjuvant alectinib 2 years vs platinum chemotherapy after resection of stage IB (≥4 cm)-IIIA ALK-positive NSCLC | Phase 3 | Positive | Disease-free survival, stage II–IIIA: 44.4 months, HR 0.24 | 257 | 86 Strong |
| 134 | BRUIN CLL-321 Relapsed/refractory CLL/SLL after a covalent BTK inhibitor: pirtobrutinib vs investigator's choice (idelalisib-rituximab or bendamustine-rituximab) | Phase 3 | Positive | Progression-free survival (median): 11.2 months vs 8.7 months, HR 0.58 | 238 | 86 Strong |
| 135 | COG ANBL0032 High-risk neuroblastoma after transplant: ch14.18 (dinutuximab) + GM-CSF + IL-2 + isotretinoin vs isotretinoin alone | Phase 3 | Positive | Event-free survival at 2 years: 66% vs 46% | 226 | 86 Strong |
| 136 | GLOW Previously untreated CLL, age ≥65 or with comorbidities, no del(17p)/TP53: fixed-duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab | Phase 3 | Positive | Progression-free survival: pending | 211 | 86 Strong |
| 137 | JUPITER-02 Untreated recurrent or metastatic nasopharyngeal carcinoma: toripalimab + gemcitabine-cisplatin vs chemotherapy | Phase 3 | Positive | Progression-free survival: pending | 289 | 86 Strong |
| 138 | KEYNOTE-177 First-line MSI-H/dMMR metastatic colorectal cancer: pembrolizumab vs investigator-choice chemotherapy | Phase 3 | Positive | Progression-free survival: 16.5 months vs 8.2 months, HR 0.6 | 307 | 86 Strong |
| 139 | LIBRETTO-431 First-line RET-fusion advanced NSCLC: selpercatinib vs platinum-pemetrexed ± pembrolizumab | Phase 3 | Positive | Progression-free survival (BICR), ITT-pembrolizumab population: 24.8 months vs 11.2 months, HR 0.46 | 261 | 86 Strong |
| 140 | LIBRETTO-531 Untreated progressive RET-mutant medullary thyroid cancer: selpercatinib vs cabozantinib or vandetanib | Phase 3 | Positive | Progression-free survival at 12 months: 86.8% vs 65.7%, HR 0.28 | 291 | 86 Strong |
| 141 | ALSYMPCA Symptomatic bone-metastatic CRPC without visceral disease: radium-223 vs placebo | Phase 3 | Positive | Overall survival: 14.9 months vs 11.3 months, HR 0.7 | 921 | 85 Strong |
| 142 | CodeBreaK 300 KRAS G12C colorectal cancer, previously treated: sotorasib + panitumumab vs standard of care | Phase 3 | Positive | Progression-free survival (BICR), sotorasib 960 mg + panitumumab: 5.6 months vs 2.2 months, HR 0.49 | 160 | 85 Strong |
| 143 | FORTITUDE-101 First-line FGFR2b-overexpressing (≥10% 2+/3+), HER2-negative advanced gastric/GEJ cancer: bemarituzumab + mFOLFOX6 vs placebo + mFOLFOX6 | Phase 3 | Mixed | Overall survival (interim): 17.9 months vs 12.5 months, HR 0.61 | 547 | 85 Strong |
| 144 | KEN SHE (single-dose HPV vaccine) Kenyan women aged 15-20: single dose of bivalent or nonavalent HPV vaccine vs meningococcal control, endpoint persistent HPV16/18 infection | Phase 3 | Positive | Vaccine efficacy against persistent HPV16/18 infection: 97.5% | 2,275 | 85 Strong |
| 145 | KEYNOTE-775 / Study 309 Advanced endometrial cancer after platinum: lenvatinib + pembrolizumab vs doxorubicin or weekly paclitaxel | Phase 3 | Positive | Overall survival (all comers): 18.3 months vs 11.4 months, HR 0.62 | 827 | 85 Strong |
| 146 | REFLECT First-line unresectable HCC: lenvatinib vs sorafenib (non-inferiority) | Phase 3 | Positive | Overall survival: 13.6 months vs 12.3 months, HR 0.92 | 954 | 85 Strong |
| 147 | ADRIATIC Limited-stage SCLC without progression after concurrent chemoradiotherapy: durvalumab consolidation (up to 2 years) vs placebo | Phase 3 | Positive | Overall survival: 55.9 months vs 33.4 months, HR 0.73 | 730 | 84 Strong |
| 148 | CELESTIAL HCC after sorafenib (up to two prior lines): cabozantinib vs placebo | Phase 3 | Positive | Overall survival: 10.2 months vs 8 months, HR 0.76 | 707 | 84 Strong |
| 149 | CheckMate 743 Unresectable pleural mesothelioma, first line: nivolumab + ipilimumab vs platinum-pemetrexed | Phase 3 | Positive | Overall survival: 18.1 months vs 14.1 months, HR 0.74 | 605 | 84 Strong |
| 150 | CheckMate 9DW First-line unresectable HCC: nivolumab + ipilimumab vs lenvatinib or sorafenib | Phase 3 | Positive | Overall survival: 23.7 months vs 20.6 months, HR 0.79 | 668 | 84 Strong |
| 151 | ECHELON-1 Untreated stage III-IV classical Hodgkin lymphoma: brentuximab vedotin + AVD vs ABVD | Phase 3 | Positive | Modified PFS at 2 years: 82.1% vs 77.2%, HR 0.77 | 1,334 | 84 Strong |
| 152 | EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9 Recurrent cervical cancer after first-line platinum: cemiplimab vs single-agent chemotherapy | Phase 3 | Positive | Overall survival: 12 months vs 8.5 months, HR 0.69 | 608 | 84 Strong |
| 153 | innovaTV 301 / ENGOT-cx12 / GOG-3057 Recurrent or metastatic cervical cancer after 1-2 prior lines including platinum: tisotumab vedotin vs investigator's-choice chemotherapy | Phase 3 | Positive | Overall survival: 11.5 months vs 9.5 months, HR 0.7 | 502 | 84 Strong |
| 154 | PANOVA-3 Unresectable locally advanced PDAC: TTFields + gemcitabine/nab-paclitaxel vs chemotherapy alone | Phase 3 | Positive | Overall survival: 16.2 months vs 14.2 months, HR 0.82 | 571 | 84 Strong |
| 155 | PROMID Treatment-naive metastatic midgut NETs: octreotide LAR vs placebo | Phase 3 | Positive | Time to tumour progression: 14.3 months vs 6 months, HR 0.34 | 85 | 84 Strong |
| 156 | RATHL Advanced Hodgkin lymphoma: interim-PET-guided omission of bleomycin (AVD) vs continued ABVD | Phase 3 | Positive | Progression-free survival at 3 years (PET2-negative): 85.7% vs 84.4% | 1,214 | 84 Strong |
| 157 | RESORCE HCC progressing on sorafenib: regorafenib vs placebo | Phase 3 | Positive | Overall survival: 10.6 months vs 7.8 months, HR 0.63 | 573 | 84 Strong |
| 158 | ALASCCA Resected stage I-III rectal or stage II-III colon cancer with somatic PIK3CA (exon 9/20) or other PI3K-pathway alterations: aspirin 160 mg/day for 3 years vs placebo | Phase 3 | Positive | Time to recurrence at 3 years, group A (PIK3CA exon 9/20): 7.7% vs 14.1%, HR 0.49 | 626 | 83 Strong |
| 159 | CLL13 / GAIA Fit, previously untreated CLL without del(17p)/TP53: chemoimmunotherapy (FCR/BR) vs venetoclax-rituximab vs venetoclax-obinutuzumab vs venetoclax-obinutuzumab-ibrutinib | Phase 3 | Positive | Undetectable MRD at month 15 (blood): 92.2% vs 86.5% vs 57% vs 52% | 926 | 83 Strong |
| 160 | IMforte First-line maintenance after induction chemo-immunotherapy in ES-SCLC: lurbinectedin + atezolizumab vs atezolizumab | Phase 3 | Positive | Overall survival: 13.2 months vs 10.6 months, HR 0.73 | 483 | 83 Strong |
| 161 | IoN Low-risk differentiated thyroid cancer (pT1-T2, N0/Nx, no adverse features) after thyroidectomy: no radioiodine vs radioiodine ablation | Phase 3 | Positive | Recurrence-free at 5 years: 98% vs 96% | 504 | 83 Strong |
| 162 | MAPS Unresectable pleural mesothelioma, first line: cisplatin-pemetrexed ± bevacizumab | Phase 3 | Positive | Overall survival: 18.8 months vs 16.1 months, HR 0.77 | 448 | 83 Strong |
| 163 | NLST & NELSON (low-dose CT screening) Annual low-dose CT versus chest X-ray (NLST, 53,454 heavy smokers) or no screening (NELSON, 15,789) in current and former smokers | Phase 3 | Positive | NLST: relative reduction in lung cancer mortality: 20% | 53,454 | 83 Strong |
| 164 | PREOPANC-1 / PREOPANC-2 Resectable and borderline-resectable PDAC: neoadjuvant chemoradiation (PREOPANC-1) or neoadjuvant FOLFIRINOX (PREOPANC-2) vs upfront surgery | Phase 3 | Mixed | Overall survival (long-term): 20.5% vs 6.5%, HR 0.73 | 246 | 83 Strong |
| 165 | RASolute 302 Metastatic PDAC after one prior line of chemotherapy: daraxonrasib vs investigator's choice chemotherapy | Phase 3 | Positive | Overall survival: 13.2 months vs 6.7 months, HR 0.4 | 460 | 83 Strong |
| 166 | CPX-351 Study 301 Newly diagnosed high-risk or secondary AML, age 60-75: CPX-351 vs conventional 7+3 | Phase 3 | Positive | Overall survival (median): 9.56 months vs 5.95 months, HR 0.69 | 309 | 82 Strong |
| 167 | DECISION Radioiodine-refractory differentiated thyroid cancer: sorafenib vs placebo | Phase 3 | Positive | Progression-free survival: 10.8 months vs 5.8 months, HR 0.59 | 417 | 82 Strong |
| 168 | DESTINY-Breast12 HER2+ metastatic breast cancer with or without brain metastases: single-arm T-DXd | Phase 3 | Positive | Intracranial objective response rate: 71.7% | 504 | 82 Strong |
| 169 | ECLIPSE PSMA-positive mCRPC after ARPI, taxane-naive: 177Lu-PSMA-I&T (7.4 GBq × 6) vs ARPI switch | Phase 3 | Positive | Radiographic progression-free survival: Met per sponsor; medians pending publication | 439 | 82 Strong |
| 170 | ISG-STS 1001 High-risk localised soft-tissue sarcoma of extremities/trunk: neoadjuvant epirubicin-ifosfamide vs histotype-tailored chemotherapy | Phase 3 | Positive | Overall survival at 46 months: 89% vs 64% | 287 | 82 Strong |
| 171 | SELECT Radioiodine-refractory differentiated thyroid cancer with progression: lenvatinib vs placebo | Phase 3 | Positive | Progression-free survival: 18.3 months vs 3.6 months, HR 0.21 | 392 | 82 Strong |
| 172 | CheckMate 816 Resectable stage IB-IIIA NSCLC: neoadjuvant nivolumab + platinum chemotherapy (3 cycles) vs chemotherapy | Phase 3 | Positive | Pathologic complete response: 24% vs 2.2% | 358 | 81 Strong |
| 173 | INO-VATE ALL Relapsed or refractory CD22+ B-ALL, adults: inotuzumab ozogamicin vs standard intensive chemotherapy | Phase 3 | Positive | Complete remission / CRi: 80.7% vs 29.4% | 326 | 81 Strong |
| 174 | COSMIC-313 Untreated intermediate/poor-risk clear-cell RCC: cabozantinib + nivolumab + ipilimumab vs nivolumab + ipilimumab | Phase 3 | Mixed | Progression-free survival: pending | 855 | 80 Strong |
| 175 | CRYSTAL & FIRE-3 First-line metastatic colorectal cancer: FOLFIRI ± cetuximab (CRYSTAL); FOLFIRI + cetuximab vs FOLFIRI + bevacizumab (FIRE-3) | Phase 3 | Positive | Overall survival, KRAS wild-type (CRYSTAL): 23.5 months vs 20 months, HR 0.8 | — | 80 Strong |
| 176 | GHSG HD21 Untreated advanced-stage classical Hodgkin lymphoma, age 18-60: PET-guided BrECADD vs escalated BEACOPP | Phase 3 | Positive | Progression-free survival at 4 years: 94.3% vs 90.9%, HR 0.66 | 1,500 | 80 Strong |
| 177 | OlympiA Adjuvant olaparib for one year in germline BRCA-mutated, HER2-negative, high-risk early breast cancer | Phase 3 | Positive | Invasive disease-free survival at 3 years: 85.9% vs 77.1%, HR 0.58 | 1,836 | 80 Strong |
| 178 | SPOTLIGHT & GLOW First-line CLDN18.2-positive (≥75% of cells), HER2-negative advanced gastric/GEJ adenocarcinoma: zolbetuximab + mFOLFOX6 (SPOTLIGHT) or CAPOX (GLOW) vs chemotherapy | Phase 3 | Positive | Overall survival (SPOTLIGHT): 18.2 months vs 15.5 months | — | 80 Strong |
| 179 | STAMPEDE Multi-arm multi-stage platform in hormone-naive advanced prostate cancer: docetaxel, abiraterone, radiotherapy to the prostate, and more added to ADT | Phase platform | Positive | Overall survival, abiraterone arm (M1 subgroup): 6-year OS 60% · 6-year OS 45% | 11,992 | 80 Strong |
| 180 | TRANSFORM Primary refractory or early-relapsed LBCL, transplant-eligible: liso-cel vs salvage + autologous transplant | Phase 3 | Positive | Event-free survival (median): 29.5 months vs 2.4 months, HR 0.36 | 184 | 80 Strong |
| 181 | CAPItello-281 De novo metastatic hormone-sensitive prostate cancer with PTEN deficiency: abiraterone + capivasertib vs abiraterone + placebo | Phase 3 | Positive | Radiographic progression-free survival, PTEN-deficient mHSPC: 40 months vs 31.7 months, HR 0.81 | 1,012 | 79 Strong |
| 182 | CARES-310 First-line unresectable HCC: camrelizumab + rivoceranib vs sorafenib | Phase 3 | Positive | Overall survival: 23.8 months vs 15.2 months, HR 0.62 | 543 | 79 Strong |
| 183 | CHALLENGE (CCTG CO.21) Resected stage III or high-risk stage II colon cancer after adjuvant chemotherapy: 3-year structured exercise programme vs health-education materials | Phase 3 | Positive | Disease-free survival at 5 years: 80.3% vs 73.9%, HR 0.72 | 889 | 79 Strong |
| 184 | DESTINY-Breast09 First-line HER2+ metastatic breast cancer: T-DXd + pertuzumab vs THP | Phase 3 | Positive | Progression-free survival (BICR), T-DXd + pertuzumab vs THP: 40.7 months vs 26.9 months, HR 0.56 | 1,157 | 79 Strong |
| 185 | EMBARK High-risk biochemical recurrence (PSA doubling time ≤9 months) after local therapy: enzalutamide + leuprolide, enzalutamide alone, or leuprolide alone | Phase 3 | Positive | Metastasis-free survival, enzalutamide + leuprolide vs leuprolide: 87.3% vs 71.4%, HR 0.42 | 1,068 | 79 Strong |
| 186 | frontMIND Untreated high-risk DLBCL (IPI 3-5): tafasitamab + lenalidomide + R-CHOP vs placebo + R-CHOP | Phase 3 | Positive | Progression-free survival at 2 years: 71.1% vs 62.9%, HR 0.75 | 899 | 79 Strong |
| 187 | Interfant-06 Infant ALL (<1 year): standard vs AML-type early intensification; transplant for high-risk KMT2A-rearranged infants | Phase 3 | Mixed | Event-free survival at 6 years: 46.1% | 651 | 79 Strong |
| 188 | KEYNOTE-564 Clear-cell RCC at intermediate-high or high risk of recurrence after nephrectomy (or M1 NED): adjuvant pembrolizumab 1 year vs placebo | Phase 3 | Positive | Disease-free survival: pending | 994 | 79 Strong |
| 189 | MARIPOSA First-line EGFR-mutant NSCLC: amivantamab + lazertinib vs osimertinib | Phase 3 | Positive | Progression-free survival (BICR): 23.7 months vs 16.6 months, HR 0.7 | 1,074 | 79 Strong |
| 190 | MSLT-II Sentinel-node-positive melanoma: immediate completion lymph node dissection vs ultrasound surveillance | Phase 3 | Positive | Melanoma-specific survival at 3 years: 86% vs 86% | 1,939 | 79 Strong |
| 191 | NRG-GY018 / KEYNOTE-868 Advanced or recurrent endometrial cancer: pembrolizumab + carboplatin-paclitaxel then pembrolizumab maintenance vs chemotherapy, analysed by MMR status | Phase 3 | Positive | Progression-free survival (dMMR): pending | 816 | 79 Strong |
| 192 | PALOMA-2 First-line postmenopausal HR+/HER2- advanced breast cancer: palbociclib + letrozole vs placebo + letrozole | Phase 3 | Mixed | Progression-free survival: 27.6 months vs 14.5 months, HR 0.56 | 666 | 79 Strong |
| 193 | PAOLA-1 / ENGOT-ov25 Newly diagnosed advanced ovarian cancer already on bevacizumab maintenance: adding olaparib vs placebo | Phase 3 | Positive | Progression-free survival (HRD-positive): 37.2 months vs 17.7 months, HR 0.33 | 806 | 79 Strong |
| 194 | PRIMA / ENGOT-OV26 Newly diagnosed advanced ovarian cancer at high risk of relapse, any BRCA/HRD status: niraparib maintenance vs placebo | Phase 3 | Mixed | Progression-free survival (HRD-positive): 21.9 months vs 10.4 months, HR 0.43 | 733 | 79 Strong |
| 195 | TROPION-Breast01 HR+/HER2- metastatic breast cancer after endocrine and 1-2 chemotherapies: Dato-DXd vs chemotherapy | Phase 3 | Mixed | Progression-free survival (BICR): 6.9 months vs 4.9 months, HR 0.63 | 732 | 79 Strong |
| 196 | TROPION-Lung01 Previously treated advanced NSCLC: Dato-DXd vs docetaxel | Phase 3 | Mixed | Progression-free survival (BICR): 4.4 months vs 3.7 months, HR 0.75 | 604 | 79 Strong |
| 197 | VERITAC-2 ER+/HER2- advanced breast cancer after CDK4/6 and endocrine therapy: vepdegestrant vs fulvestrant | Phase 3 | Mixed | Progression-free survival, ESR1-mutant (BICR): 5 months vs 2.1 months, HR 0.57 | 624 | 79 Strong |
| 198 | ADAURA Adjuvant osimertinib 3 years after resection of stage IB-IIIA EGFR-mutant NSCLC | Phase 3 | Positive | Disease-free survival, stage II–IIIA: 19.6 months, HR 0.17 | 682 | 78 Strong |
| 199 | ATHENA-MONO / GOG-3020 Newly diagnosed advanced ovarian cancer after response to first-line platinum: rucaparib maintenance vs placebo | Phase 3 | Positive | Progression-free survival (ITT): 20.2 months vs 9.2 months, HR 0.52 | 538 | 78 Strong |
| 200 | DUO-E / GOG-3041 / ENGOT-EN10 Newly diagnosed advanced or recurrent endometrial cancer: chemotherapy + durvalumab, then durvalumab ± olaparib maintenance, vs chemotherapy | Phase 3 | Positive | Progression-free survival (dMMR, durvalumab): pending | 718 | 78 Strong |
| 201 | EF-14 Newly diagnosed glioblastoma after chemoradiation: TTFields + maintenance temozolomide vs temozolomide alone | Phase 3 | Positive | Progression-free survival: 6.7 months vs 4 months, HR 0.63 | 695 | 78 Strong |
| 202 | EMERALD-3 Embolisation-eligible unresectable HCC: STRIDE (durvalumab + tremelimumab) + lenvatinib + TACE vs TACE | Phase 3 | Positive | Progression-free survival: pending | 725 | 78 Strong |
| 203 | Euro Ewing 2012 Newly diagnosed Ewing sarcoma: VDC/IE (US-style) vs VIDE/VAI (European) induction/consolidation | Phase 3 | Positive | Event-free survival at 3 years: 67% vs 61%, HR 0.71 | 640 | 78 Strong |
| 204 | HER2CLIMB-02 HER2+ metastatic breast cancer after trastuzumab and taxane: tucatinib + T-DM1 vs placebo + T-DM1 | Phase 3 | Mixed | Progression-free survival: 9.5 months vs 7.4 months, HR 0.76 | 463 | 78 Strong |
| 205 | INT-0091 (Ewing sarcoma) Newly diagnosed Ewing sarcoma: VDC alone vs VDC alternating with ifosfamide-etoposide | Phase 3 | Positive | Event-free survival at 5 years (localised): 69% vs 54% | 518 | 78 Strong |
| 206 | KEYNOTE-689 Resectable stage III-IVA HNSCC: neoadjuvant pembrolizumab, surgery, then adjuvant pembrolizumab with (chemo)radiation vs surgery and (chemo)radiation | Phase 3 | Positive | Event-free survival (CPS ≥1): 59.7 months vs 29.6 months | 714 | 78 Strong |
| 207 | MAGNITUDE First-line mCRPC: abiraterone + niraparib vs abiraterone + placebo, HRR-mutant and HRR-negative cohorts | Phase 3 | Mixed | Radiographic progression-free survival, BRCA1/2 subgroup: 16.6 months vs 10.9 months, HR 0.53 | 423 | 78 Strong |
| 208 | MajesTEC-3 Relapsed/refractory myeloma after 1-3 prior lines: teclistamab + daratumumab vs Dara-Pd or Dara-Vd | Phase 3 | Positive | Progression-free survival at 36 months: 83.4% vs 29.7%, HR 0.17 | 587 | 78 Strong |
| 209 | RADIANT-3 and RADIANT-4 Progressive pancreatic NETs (RADIANT-3, n=410) and lung/GI NETs (RADIANT-4, n=302): everolimus vs placebo | Phase 3 | Positive | Progression-free survival (RADIANT-3): 11 months vs 4.6 months, HR 0.35 | 712 | 78 Strong |
| 210 | ACE-Breast-02 HER2+ advanced breast cancer after trastuzumab and taxane (China): ARX788 vs lapatinib + capecitabine | Phase 3 | Positive | Progression-free survival: 11.3 months vs 8.2 months, HR 0.64 | 441 | 77 Strong |
| 211 | AETHERA High-risk Hodgkin lymphoma after autologous transplant: brentuximab vedotin consolidation vs placebo | Phase 3 | Positive | Progression-free survival (median): 42.9 months vs 24.1 months, HR 0.57 | 329 | 77 Strong |
| 212 | BEATcc / ENGOT-Cx10 / GOG-3030 Metastatic, persistent, or recurrent cervical cancer, first line: atezolizumab + cisplatin/carboplatin-paclitaxel + bevacizumab vs the same without atezolizumab | Phase 3 | Positive | Progression-free survival: 13.7 months vs 10.4 months, HR 0.62 | 410 | 77 Strong |
| 213 | COMPASSION-16 / AK104-303 Persistent, recurrent, or metastatic cervical cancer, first line (China): cadonilimab (PD-1×CTLA-4 bispecific) + platinum-paclitaxel ± bevacizumab vs placebo + chemotherapy ± bevacizumab | Phase 3 | Positive | Progression-free survival: pending | 445 | 77 Strong |
| 214 | ESTIMABL2 Low-risk differentiated thyroid cancer (pT1a-T1b N0/Nx) after total thyroidectomy: no radioiodine vs 1.1 GBq ablation | Phase 3 | Positive | Patients without events at 3 years: 95.6% vs 95.9% | 776 | 77 Strong |
| 215 | HARMONi-2 First-line PD-L1-positive (TPS ≥1%) advanced NSCLC in China: ivonescimab vs pembrolizumab monotherapy | Phase 3 | Positive | Progression-free survival (IRRC): 11.1 months vs 5.8 months, HR 0.51 | 398 | 77 Strong |
| 216 | IMROZ Newly diagnosed transplant-ineligible myeloma (age ≤80): Isa-VRd vs VRd | Phase 3 | Positive | Progression-free survival at 60 months: 63.2% vs 45.2%, HR 0.6 | 446 | 77 Strong |
| 217 | INAVO120 First-line PIK3CA-mutant HR+/HER2- advanced breast cancer relapsing on/after adjuvant endocrine therapy: inavolisib + palbociclib + fulvestrant vs placebo + palbociclib + fulvestrant | Phase 3 | Positive | Progression-free survival: 15 months vs 7.3 months, HR 0.43 | 325 | 77 Strong |
| 218 | INDIGO Residual or recurrent grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, no prior RT/chemo: vorasidenib vs placebo | Phase 3 | Positive | Progression-free survival (BIRC): 27.7 months vs 11.1 months, HR 0.39 | 331 | 77 Strong |
| 219 | KarMMa-3 Triple-class-exposed myeloma after 2-4 prior lines: ide-cel vs standard regimens | Phase 3 | Positive | Progression-free survival (median): 13.3 months vs 4.4 months, HR 0.49 | 386 | 77 Strong |
| 220 | MIRASOL / GOG-3045 Platinum-resistant ovarian cancer with high folate receptor alpha expression, 1-3 prior lines: mirvetuximab soravtansine vs chemotherapy | Phase 3 | Positive | Progression-free survival: 5.62 months vs 3.98 months, HR 0.65 | 453 | 77 Strong |
| 221 | ROSELLA / GOG-3073 Platinum-resistant ovarian cancer, 1-3 prior lines: relacorilant + nab-paclitaxel vs nab-paclitaxel | Phase 3 | Positive | Progression-free survival: 6.5 months vs 5.5 months, HR 0.7 | 381 | 77 Strong |
| 222 | SSGXVIII/AIO (adjuvant imatinib in GIST) High-risk resected GIST: adjuvant imatinib 3 years vs 1 year | Phase 3 | Positive | Recurrence-free survival at 5 years: 65.6% vs 47.9%, HR 0.46 | 400 | 77 Strong |
| 223 | CABINET (Alliance A021602) Previously treated advanced pancreatic (n=95) and extra-pancreatic (n=203) NETs: cabozantinib vs placebo | Phase 3 | Positive | Progression-free survival (pancreatic NET): 13.8 months vs 4.4 months, HR 0.23 | 298 | 76 Strong |
| 224 | CLARINET Non-functioning enteropancreatic NETs, grade 1-2: lanreotide 120 mg vs placebo | Phase 3 | Positive | Progression-free survival: 18 months, HR 0.47 | 204 | 76 Strong |
| 225 | COMPETE Progressive grade 1-2 SSTR-positive GEP-NETs: 177Lu-edotreotide vs everolimus | Phase 3 | Positive | Progression-free survival: 23.9 months vs 14.1 months, HR 0.67 | 309 | 76 Strong |
| 226 | CROWN First-line ALK-positive advanced NSCLC: lorlatinib vs crizotinib | Phase 3 | Positive | Progression-free survival at 5 years (BICR): 60% vs 8%, HR 0.19 | 296 | 76 Strong |
| 227 | DREAMM-8 Relapsed myeloma after ≥1 line including lenalidomide: belantamab-Pd vs Pom-Vd | Phase 3 | Positive | Progression-free survival at 12 months: 71% vs 51%, HR 0.52 | 302 | 76 Strong |
| 228 | HiLo Differentiated thyroid cancer needing ablation: low-dose (1.1 GBq) vs high-dose (3.7 GBq) radioiodine, with recombinant TSH or thyroid hormone withdrawal | Phase 3 | Positive | Successful ablation: 85% vs 88.9% | 438 | 76 Strong |
| 229 | KEYNOTE-204 Relapsed/refractory classical Hodgkin lymphoma: pembrolizumab vs brentuximab vedotin | Phase 3 | Positive | Progression-free survival (median): 13.2 months vs 8.3 months, HR 0.65 | 304 | 76 Strong |
| 230 | LAURA Unresectable stage III EGFR-mutant NSCLC after chemoradiation: osimertinib until progression vs placebo | Phase 3 | Positive | Progression-free survival (BICR): 39.1 months vs 5.6 months, HR 0.16 | 216 | 76 Strong |
| 231 | LITESPARK-022 Clear-cell RCC at high risk after nephrectomy: adjuvant pembrolizumab + belzutifan vs pembrolizumab + placebo | Phase 3 | Positive | — | 1,600 | 76 Strong |
| 232 | PRECISION Biopsy-naive men with raised PSA: MRI-targeted biopsy (biopsy only if MRI positive) vs standard TRUS biopsy | Phase 3 | Positive | Detection of clinically significant cancer: 38% vs 26% | 500 | 76 Strong |
| 233 | SERENA-6 First-line HR+/HER2- advanced breast cancer on AI + CDK4/6 with an ESR1 mutation detected in ctDNA before radiographic progression: switch to camizestrant + CDK4/6 vs continue AI + CDK4/6 | Phase 3 | Positive | Progression-free survival: 16 months vs 9.2 months, HR 0.44 | 315 | 76 Strong |
| 234 | AGILE Newly diagnosed IDH1-mutated AML unfit for intensive chemotherapy: ivosidenib + azacitidine vs placebo + azacitidine | Phase 3 | Positive | Event-free survival: pending | 146 | 75 Strong |
| 235 | ClarIDHy Previously treated IDH1-mutant cholangiocarcinoma: ivosidenib vs placebo | Phase 3 | Positive | Progression-free survival: 2.7 months vs 1.4 months, HR 0.37 | 187 | 75 Strong |
| 236 | DeFi Progressing desmoid tumours: nirogacestat vs placebo | Phase 3 | Positive | Progression-free survival: pending | 142 | 75 Strong |
| 237 | EPCORE DLBCL-1 R/R DLBCL after ≥1 line, transplant-ineligible: epcoritamab monotherapy vs investigator's choice (R-GemOx or BR) | Phase 3 | Mixed | Overall survival: pending | 552 | 75 Strong |
| 238 | INVICTUS Advanced GIST after ≥3 kinase inhibitors: ripretinib vs placebo | Phase 3 | Positive | Progression-free survival (median): 6.3 months vs 1 months, HR 0.15 | 129 | 75 Strong |
| 239 | KEYNOTE-716 Resected stage IIB or IIC melanoma: adjuvant pembrolizumab 1 year vs placebo | Phase 3 | Positive | — | 976 | 75 Strong |
| 240 | proPSMA High-risk localised prostate cancer staging: PSMA PET/CT vs CT + bone scan | Phase 3 | Positive | Accuracy for pelvic nodal or distant metastases (AUC): 92% vs 65% | 302 | 75 Strong |
| 241 | BREAKWATER First-line BRAF V600E-mutant metastatic colorectal cancer: encorafenib + cetuximab + mFOLFOX6 (or FOLFIRI) vs chemotherapy ± bevacizumab | Phase 3 | Positive | Progression-free survival (EC + mFOLFOX6): 12.8 months vs 7.1 months | — | 74 Solid |
| 242 | HERTHENA-Lung02 EGFR-mutant NSCLC after third-generation TKI: patritumab deruxtecan vs platinum chemotherapy | Phase 3 | Mixed | Progression-free survival (BICR): 5.8 months vs 5.4 months, HR 0.77 | 586 | 74 Solid |
| 243 | KEYNOTE-B96 / ENGOT-ov65 Platinum-resistant recurrent ovarian cancer, 1-2 prior lines: pembrolizumab + weekly paclitaxel ± bevacizumab vs placebo + paclitaxel ± bevacizumab | Phase 3 | Positive | Progression-free survival (CPS ≥1): 8.3 months vs 7.2 months, HR 0.72 | — | 74 Solid |
| 244 | RTOG 0129 (HPV analysis) Stage III-IV oropharyngeal and other HNSCC: accelerated vs standard fractionation chemoradiation; retrospective HPV analysis | Phase 3 | Completed | Overall survival at 3 years by HPV status: 82.4% vs 57.1% | 743 | 74 Solid |
| 245 | COG ANBL0532 High-risk neuroblastoma: tandem vs single autologous transplant after induction | Phase 3 | Positive | Event-free survival at 3 years: 61.6% vs 48.4% | 652 | 73 Solid |
| 246 | COMBI-AD Resected stage III BRAF V600-mutant melanoma: adjuvant dabrafenib + trametinib 1 year vs placebo | Phase 3 | Positive | Relapse-free survival at 10 years: 48% vs 32% | 870 | 73 Solid |
| 247 | DESTINY-Breast11 Neoadjuvant high-risk HER2+ early breast cancer: T-DXd followed by THP vs ddAC-THP | Phase 3 | Positive | Pathologic complete response (ypT0/Tis ypN0): 67.3% vs 56.3% | 927 | 73 Solid |
| 248 | GOG-0218 & ICON7 (bevacizumab) Newly diagnosed advanced ovarian cancer: carboplatin-paclitaxel ± bevacizumab with bevacizumab maintenance | Phase 3 | Mixed | Progression-free survival (GOG-0218): 14.1 months vs 10.3 months, HR 0.72 | 3,401 | 73 Solid |
| 249 | KEYNOTE-522 Early-stage (II-III) TNBC: pembrolizumab + chemotherapy before surgery, pembrolizumab after | Phase 3 | Positive | Pathologic complete response (ypT0/Tis ypN0): 64.8% vs 51.2% | 1,174 | 73 Solid |
| 250 | Krascendo 1 Previously treated KRAS G12C NSCLC: divarasib vs sotorasib or adagrasib | Phase 3 | Positive | — | 320 | 73 Solid |
| 251 | SIOPEN HR-NBL1 High-risk neuroblastoma (Europe): multiple randomisations, including busulfan-melphalan vs CEM conditioning and dinutuximab beta ± IL-2 | Phase 3 | Mixed | Event-free survival at 3 years (R1 conditioning): 50% vs 38% | 3,700 | 73 Solid |
| 252 | SPLASH PSMA-positive mCRPC after one ARPI, taxane-naive: 177Lu-PNT2002 vs ARPI switch | Phase 3 | Mixed | Radiographic progression-free survival: 9.5 months vs 6 months, HR 0.71 | 412 | 73 Solid |
| 253 | STARGLO R/R DLBCL, transplant-ineligible, ≥1 prior line: glofitamab + GemOx vs rituximab + GemOx | Phase 3 | Mixed | Overall survival (median): 25.5 months vs 12.9 months, HR 0.62 | 274 | 73 Solid |
| 254 | APT (adjuvant paclitaxel-trastuzumab) Small (≤3 cm), node-negative HER2+ breast cancer: 12 weeks paclitaxel + 1 year trastuzumab | Phase 2 | Positive | 7-year disease-free survival: 93% | 410 | 72 Solid |
| 255 | BL-B01D1-307 Previously treated locally advanced or metastatic TNBC: izalontamab brengitecan vs chemotherapy | Phase 3 | Positive | Progression-free survival (BICR): 8.5 months vs 3.1 months, HR 0.29 | 418 | 72 Solid |
| 256 | PHERGain HER2+ early breast cancer: chemotherapy-free trastuzumab + pertuzumab with early 18F-FDG PET response assessment to decide whether chemotherapy is needed | Phase 2 | Positive | 3-year invasive disease-free survival (PET-adapted arm): 95.4% | 356 | 72 Solid |
| 257 | SANET-ep and SANET-p Progressive extra-pancreatic (n=198) and pancreatic (n=172) NETs: surufatinib vs placebo (China) | Phase 3 | Positive | Progression-free survival (SANET-ep): 9.2 months vs 3.8 months, HR 0.33 | 369 | 72 Solid |
| 258 | CEPHEUS Newly diagnosed transplant-ineligible or -deferred myeloma: Dara-VRd vs VRd | Phase 3 | Positive | MRD negativity (10⁻⁵): 60.9% vs 39.4% | 395 | 71 Solid |
| 259 | SWOG S1801 Resectable stage IIIB-IV melanoma: three doses of pembrolizumab before surgery then 15 after, vs 18 doses after surgery | Phase 2 | Positive | Event-free survival at 2 years: 72% vs 49%, HR 0.58 | 313 | 71 Solid |
| 260 | CONVERT Limited-stage SCLC: twice-daily 45 Gy vs once-daily 66 Gy thoracic radiotherapy with concurrent cisplatin-etoposide | Phase 3 | Mixed | Overall survival: 30 months vs 25 months, HR 1.18 | 547 | 70 Solid |
| 261 | DUO-O / ENGOT-ov46 Newly diagnosed non-BRCA-mutated advanced ovarian cancer: chemotherapy + bevacizumab + durvalumab, then durvalumab + bevacizumab ± olaparib maintenance, vs standard | Phase 3 | Mixed | Progression-free survival (non-tBRCAm ITT): pending | 1,130 | 70 Solid |
| 262 | IMpassion130 First-line metastatic TNBC: atezolizumab + nab-paclitaxel | Phase 3 | Mixed | Progression-free survival, PD-L1+ (SP142 IC ≥1%): 7.5 months vs 5 months, HR 0.62 | 902 | 70 Solid |
| 263 | PhALLCON Newly diagnosed Ph-positive ALL, adults: ponatinib vs imatinib, each with reduced-intensity chemotherapy | Phase 3 | Positive | MRD-negative complete remission at end of induction: 34.4% vs 16.7% | 245 | 70 Solid |
| 264 | RELATIVITY-047 Untreated unresectable or metastatic melanoma: nivolumab + relatlimab (fixed dose) vs nivolumab | Phase 2/3 | Positive | Progression-free survival: 10.1 months vs 4.6 months, HR 0.75 | 714 | 70 Solid |
| 265 | BILCAP Adjuvant capecitabine for 6 months vs observation after resection of biliary tract cancer | Phase 3 | Mixed | Overall survival (ITT): 51.1 months vs 36.4 months, HR 0.81 | 447 | 69 Solid |
| 266 | CheckMate 577 Resected oesophageal/GEJ cancer with residual disease after neoadjuvant chemoradiation: adjuvant nivolumab 1 year vs placebo | Phase 3 | Mixed | Disease-free survival: 22.4 months vs 11 months, HR 0.69 | 794 | 69 Solid |
| 267 | EMERALD-1 Embolisation-eligible unresectable HCC: TACE + durvalumab ± bevacizumab vs TACE + placebo | Phase 3 | Mixed | Progression-free survival: 15 months vs 8.2 months, HR 0.77 | 616 | 69 Solid |
| 268 | ROMANA 1 and ROMANA 2 Unresectable stage III/IV NSCLC with cachexia (weight loss over 5% in 6 months or BMI under 20): anamorelin 100 mg/day vs placebo for 12 weeks | Phase 3 | Mixed | Change in lean body mass over 12 weeks (ROMANA 1): 0.99 kg vs -0.47 kg | 979 | 69 Solid |
| 269 | D-ALBA (GIMEMA LAL2116) Newly diagnosed Ph-positive ALL, adults of all ages: dasatinib induction followed by blinatumomab, no systemic chemotherapy | Phase 2 | Positive | Disease-free survival at 18 months: 88% | 63 | 68 Solid |
| 270 | LEAP-012 Unresectable non-metastatic HCC: TACE + lenvatinib + pembrolizumab vs TACE + placebo | Phase 3 | Mixed | Progression-free survival: 14.6 months vs 10 months, HR 0.66 | 480 | 68 Solid |
| 271 | MOTION Symptomatic tenosynovial giant cell tumour not amenable to surgery: vimseltinib vs placebo | Phase 3 | Positive | Objective response rate at week 25: 40% vs 0% | 123 | 68 Solid |
| 272 | NHS-Galleri 140,000 asymptomatic adults aged 50-77 randomised to annual Galleri testing or control for 3 years | Phase 3 | Completed | Stage III–IV incidence, 12 prespecified cancers (primary): Not met: no statistically significant reduction within one year of the last screen; a fall in stage IV was offset by a rise in stage III. | 142,000 | 68 Solid |
| 273 | PANKU-Esophagus01 (BL-B01D1-305) Recurrent or metastatic oesophageal squamous cell carcinoma after PD-(L)1 inhibitor plus platinum chemotherapy: izalontamab brengitecan vs chemotherapy of physician's choice | Phase 3 | Positive | — | 497 | 68 Solid |
| 274 | DYNAMIC Stage II colon cancer: ctDNA-guided adjuvant chemotherapy vs standard management | Phase 2 | Positive | Recurrence-free survival at 2 years (non-inferiority): 93.5% vs 92.4% | 455 | 67 Solid |
| 275 | PREHAB: multimodal prehabilitation before colorectal cancer surgery Non-metastatic colorectal cancer scheduled for elective resection within an ERAS pathway: 4-week supervised multimodal prehabilitation (high-intensity exercise, nutrition, psychological support, smoking cessation) vs ERAS alone | Phase 3 | Positive | — | 251 | 67 Solid |
| 276 | CAPTIVATE Previously untreated CLL, age ≤70: 3 cycles ibrutinib lead-in then 12 cycles ibrutinib + venetoclax (fixed-duration cohort n=159; MRD-guided cohort n=164) | Phase 2 | Positive | Complete response (fixed-duration cohort): 55% | 323 | 66 Solid |
| 277 | POLO Germline BRCA-mutated metastatic PDAC not progressed on ≥16 weeks of platinum: olaparib maintenance vs placebo | Phase 3 | Mixed | Progression-free survival: 7.4 months vs 3.8 months, HR 0.53 | 154 | 66 Solid |
| 278 | CAMBRIA-1 & CAMBRIA-2 Adjuvant ER+/HER2- early breast cancer: camizestrant vs standard endocrine therapy, either after 2-5 years of prior ET (CAMBRIA-1) or upfront (CAMBRIA-2) | Phase 3 | Recruiting | — | 10,000 | 65 Solid |
| 279 | STELLAR Unresectable pleural mesothelioma, first line: TTFields (150 kHz) + platinum-pemetrexed, single arm | Phase 2 | Positive | Overall survival (single arm vs historical): 18.2 months vs 12.1 months | 80 | 65 Solid |
| 280 | TheraP (ANZUP 1603) mCRPC after docetaxel: 177Lu-PSMA-617 vs cabazitaxel, PSMA PET/FDG PET selected | Phase 2 | Positive | PSA response ≥50%: 66% vs 37% | 200 | 65 Solid |
| 281 | BEAT-meso (ETOP 13-18) Advanced pleural mesothelioma, first line: bevacizumab + carboplatin-pemetrexed ± atezolizumab | Phase 3 | Mixed | — | 400 | 64 Solid |
| 282 | C-144-01 Advanced melanoma progressing after anti-PD-1 (and BRAF/MEK if applicable): single infusion of lifileucel TIL | Phase 2 | Positive | Objective response rate: 31.4% | 153 | 64 Solid |
| 283 | ProtecT PSA-detected localised prostate cancer: active monitoring vs prostatectomy vs radiotherapy | Phase 3 | Completed | Prostate-cancer-specific mortality at 15 years: 3.1% vs 2.2% vs 2.9% | 1,643 | 64 Solid |
| 284 | ASCERTAIN-V Newly diagnosed AML unfit for intensive induction: oral decitabine-cedazuridine + venetoclax | Phase 2 | Positive | Complete remission: 41.6% | 101 | 63 Solid |
| 285 | BOND-003 BCG-unresponsive high-risk NMIBC with CIS: intravesical cretostimogene grenadenorepvec, single arm (cohort C) | Phase 3 | Positive | Complete response at any time: 75.2% | 110 | 63 Solid |
| 286 | DESTINY-CRC02 Pretreated HER2-positive metastatic colorectal cancer: T-DXd 5.4 vs 6.4 mg/kg | Phase 2 | Positive | Objective response rate: 37.8 percent vs 27.5 percent | 122 | 63 Solid |
| 287 | ELIANA Relapsed or refractory B-ALL, patients aged 3-25: single infusion of tisagenlecleucel | Phase 2 | Positive | Overall remission rate within 3 months: 81% | 97 | 63 Solid |
| 288 | Low-dose olanzapine for cancer anorexia (Tata Memorial) Untreated, locally advanced or metastatic gastric, hepatopancreaticobiliary or lung cancer starting chemotherapy: olanzapine 2.5 mg daily vs placebo for 12 weeks, plus standard nutritional advice | Phase 3 | Positive | Weight gain greater than 5% at 12 weeks: 60% vs 9% | 124 | 63 Solid |
| 289 | SUNMO R/R LBCL, transplant-ineligible: mosunetuzumab + polatuzumab vs R-GemOx | Phase 3 | Positive | — | 208 | 62 Solid |
| 290 | ROAR (anaplastic thyroid cancer cohort) BRAF V600E-mutant anaplastic thyroid cancer: dabrafenib + trametinib | Phase 2 | Positive | Objective response rate: 56% | 36 | 61 Solid |
| 291 | EV-304 / KEYNOTE-B15 Cisplatin-eligible MIBC: perioperative enfortumab vedotin + pembrolizumab vs neoadjuvant gemcitabine-cisplatin, both with cystectomy | Phase 3 | Positive | — | — | 60 Solid |
| 292 | ATLANTIS Relapsed SCLC after one platinum line: lurbinectedin + doxorubicin vs topotecan or CAV | Phase 3 | Negative | Overall survival: 8.6 months vs 7.6 months, HR 0.97 | 613 | 59 Solid |
| 293 | CheckMate 548 & CheckMate 143 & CheckMate 498 Glioblastoma: nivolumab added to standard therapy (newly diagnosed, MGMT-methylated CM548; MGMT-unmethylated vs temozolomide CM498) and nivolumab vs bevacizumab at recurrence (CM143) | Phase 3 | Negative | Overall survival, MGMT-methylated glioblastoma: 28.9 months vs 32.1 months, HR 1.1 | 716 | 59 Solid |
| 294 | INSIGHT Second-line GIST with KIT exon 11 + exon 17/18 mutations (ctDNA-selected): ripretinib vs sunitinib | Phase 3 | Positive | — | 54 | 59 Solid |
| 295 | NMTRC003/003B (DFMO maintenance) High-risk neuroblastoma in remission after standard therapy including anti-GD2: 2 years of oral eflornithine (single arm, externally controlled) | Phase 2 | Positive | Event-free survival: pending | 105 | 59 Solid |
| 296 | Ponsegromab phase 2 in cancer cachexia NSCLC, pancreatic or colorectal cancer with cachexia and elevated serum GDF-15: ponsegromab 100, 200 or 400 mg subcutaneously every 4 weeks vs placebo for 12 weeks | Phase 2 | Positive | Change in body weight at 12 weeks (placebo-adjusted): 2.81 kg vs 1.92 kg vs 1.22 kg vs 0 kg | 187 | 59 Solid |
| 297 | PALLAS & PENELOPE-B Adjuvant palbociclib + endocrine therapy in HR+/HER2- early breast cancer (PALLAS, 2 years; PENELOPE-B, 1 year after residual disease) | Phase 3 | Negative | 4-year invasive disease-free survival (PALLAS): 84.2% vs 84.5%, HR 0.96 | 6,862 | 58 Solid |
| 298 | FELIX Relapsed or refractory B-ALL, adults: obecabtagene autoleucel single split-dose course | Phase 1/2 | Positive | Overall remission (CR + CRi): 77% | 153 | 57 Solid |
| 299 | TRANSCEND CLL 004 Relapsed/refractory CLL/SLL after BTK inhibitor (and venetoclax in the primary analysis set): lisocabtagene maraleucel | Phase 1/2 | Positive | Complete response / CRi (primary analysis set): 18% | 137 | 57 Solid |
| 300 | AUGMENT-101 Relapsed/refractory KMT2A-rearranged or NPM1-mutated acute leukaemia: revumenib monotherapy | Phase 1/2 | Positive | CR + CRh (KMT2Ar cohort): 22.8% | 94 | 56 Solid |
| 301 | AZUR-1 Untreated stage II/III dMMR/MSI-H locally advanced rectal cancer: dostarlimab monotherapy for 6 months, no surgery or radiation if complete response | Phase 2 | Positive | — | 154 | 56 Solid |
| 302 | HARMONi-3 First-line metastatic squamous and non-squamous NSCLC, global: ivonescimab + chemotherapy vs pembrolizumab + chemotherapy | Phase 3 | Mixed | — | 1,080 | 56 Solid |
| 303 | KOMET-001 Relapsed/refractory NPM1-mutated AML: ziftomenib 600 mg daily monotherapy | Phase 1/2 | Positive | Complete remission: 23% | 112 | 56 Solid |
| 304 | CheckMate 205 Relapsed/refractory classical Hodgkin lymphoma after autologous transplant: nivolumab (cohorts A-C); cohort D nivolumab-AVD frontline | Phase 2 | Positive | Objective response rate: 69% | 243 | 55 Solid |
| 305 | DESTINY-PanTumor02 HER2-expressing (IHC 2+/3+) solid tumours after ≥1 line, seven cohorts including endometrial and cervical: trastuzumab deruxtecan | Phase 2 | Positive | Objective response rate, endometrial cohort: 57.5% vs 84.6% | 267 | 55 Solid |
| 306 | BWEL (Breast Cancer Weight Loss, Alliance A011401) Stage II-III HR-positive or HER2-positive breast cancer, BMI at least 27: 2-year telephone-based weight-loss intervention plus health education vs health education alone | Phase 3 | Mixed | — | 3,181 | 54 Solid |
| 307 | EPCORE NHL-1 R/R LBCL after ≥2 lines (single-arm expansion): epcoritamab monotherapy | Phase 2 | Positive | Objective response rate: 63.1% | 157 | 54 Solid |
| 308 | FIGHT-202 Previously treated cholangiocarcinoma with FGFR2 fusions (cohort A): pemigatinib single arm | Phase 2 | Positive | Objective response rate: 35.5% | 147 | 54 Solid |
| 309 | LOTIS-2 R/R DLBCL after ≥2 lines: loncastuximab tesirine (single arm) | Phase 2 | Positive | Objective response rate: 48.3% | 145 | 54 Solid |
| 310 | persevERA First-line ER+/HER2- advanced breast cancer: giredestrant + palbociclib vs letrozole + palbociclib | Phase 3 | Negative | Progression-free survival (investigator): 33.1 months vs 28.2 months | 978 | 54 Solid |
| 311 | TROPION-Lung05 Actionable-genomic-alteration NSCLC after targeted therapy and platinum: datopotamab deruxtecan single arm | Phase 2 | Positive | Objective response rate (BICR): 35.8% vs 43.6% | 137 | 54 Solid |
| 312 | CONTACT-03 Advanced RCC progressing on or after a PD-1/PD-L1 inhibitor: atezolizumab + cabozantinib vs cabozantinib | Phase 3 | Negative | Progression-free survival: 10.6 months vs 10.8 months, HR 1.03 | 522 | 53 Solid |
| 313 | FOENIX-CCA2 Previously treated FGFR2-rearranged intrahepatic cholangiocarcinoma: futibatinib single arm | Phase 2 | Positive | Objective response rate: 42% | 103 | 53 Solid |
| 314 | FOURLIGHT-1 HR+/HER2- advanced breast cancer after CDK4/6 inhibitor: atirmociclib + fulvestrant vs fulvestrant | Phase 2 | Positive | — | 400 | 53 Solid |
| 315 | IMbrave050 Adjuvant atezolizumab + bevacizumab vs active surveillance after resection or ablation of high-risk HCC | Phase 3 | Negative | Recurrence-free survival (interim): pending | 668 | 53 Solid |
| 316 | L-MIND R/R DLBCL, transplant-ineligible, 1-3 prior lines: tafasitamab + lenalidomide (single arm) | Phase 2 | Positive | Objective response rate: 60% | 81 | 53 Solid |
| 317 | MagnetisMM-3 Relapsed/refractory myeloma after ≥3 lines, BCMA-naive: elranatamab monotherapy | Phase 2 | Positive | Objective response rate: 61% | 123 | 53 Solid |
| 318 | MARS 2 Resectable pleural mesothelioma: extended pleurectomy/decortication + chemotherapy vs chemotherapy alone | Phase 3 | Negative | Overall survival: 19.3 months vs 24.8 months, HR 1.28 | 335 | 53 Solid |
| 319 | NICHE-2 Locally advanced (mostly stage III) dMMR colon cancer: 4 weeks of neoadjuvant nivolumab + one dose ipilimumab, then surgery | Phase 2 | Positive | Pathologic complete response: 68 percent | 115 | 53 Solid |
| 320 | Naxitamab Study 201 Relapsed/refractory high-risk neuroblastoma in bone/bone marrow: naxitamab + GM-CSF | Phase 2 | Positive | Objective response rate: 50% | 74 | 52 Solid |
| 321 | SCARLET (SWOG S2212) Stage II-III TNBC: anthracycline-free carboplatin/docetaxel + pembrolizumab vs KEYNOTE-522 regimen | Phase 3 | Recruiting | — | 2,400 | 52 Solid |
| 322 | TiNivo-2 Advanced RCC after progression on a PD-1/PD-L1 inhibitor: tivozanib + nivolumab vs tivozanib | Phase 3 | Negative | Progression-free survival: 5.7 months vs 7.4 months, HR 1.1 | 343 | 52 Solid |
| 323 | ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63) Stage II–III TNBC with residual invasive disease after neoadjuvant therapy and surgery: adjuvant sacituzumab govitecan + pembrolizumab vs pembrolizumab ± capecitabine | Phase 3 | Active | — | 1,514 | 51 Solid |
| 324 | OptimICE-pCR (A012103) Stage II-III TNBC with pathologic complete response after KEYNOTE-522 regimen: adjuvant pembrolizumab vs observation | Phase 3 | Recruiting | — | 1,295 | 51 Solid |
| 325 | WHEL (Women's Healthy Eating and Living) Early-stage breast cancer survivors within 4 years of diagnosis: intensive telephone counselling for a diet very high in vegetables, fruit and fibre and low in fat vs printed dietary guidelines | Phase 3 | Negative | Invasive breast cancer event (recurrence or new primary): 16.7% vs 16.9%, HR 0.96 | 3,088 | 51 Solid |
| 326 | Add-Aspirin After curative treatment for breast, colorectal, gastro-oesophageal or prostate cancer: aspirin 100 mg vs 300 mg vs placebo daily for 5 years | Phase 3 | Active | — | 11,000 | 50 Solid |
| 327 | CLARITY-Gastric 01 Second- or later-line CLDN18.2-positive advanced gastric/GEJ cancer: sonesitatug vedotin (AZD0901/CMG901) vs investigator's choice | Phase 3 | Positive | — | — | 50 Solid |
| 328 | OUTBACK / ANZGOG 0902 / GOG-0274 Locally advanced cervical cancer: chemoradiation followed by 4 cycles adjuvant carboplatin-paclitaxel vs chemoradiation alone | Phase 3 | Negative | Overall survival at 5 years: 72% vs 71%, HR 0.91 | 919 | 50 Solid |
| 329 | TROPION-Breast03 Stage I–III TNBC with residual invasive disease after neoadjuvant therapy: adjuvant Dato-DXd ± durvalumab vs investigator's choice (capecitabine, pembrolizumab, or both) | Phase 3 | Active | — | 1,075 | 50 Solid |
| 330 | ANNOUNCE Advanced soft-tissue sarcoma, first line: olaratumab + doxorubicin vs doxorubicin | Phase 3 | Negative | Overall survival (median): 20.4 months vs 19.7 months, HR 1.05 | 509 | 49 Emerging |
| 331 | DeLLphi-305 First-line maintenance in ES-SCLC after platinum-etoposide-durvalumab: tarlatamab + durvalumab vs durvalumab | Phase 3 | Recruiting | — | 550 | 49 Emerging |
| 332 | LEAP-002 First-line unresectable HCC: lenvatinib + pembrolizumab vs lenvatinib | Phase 3 | Negative | Overall survival: 21.2 months vs 19 months, HR 0.84 | 794 | 49 Emerging |
| 333 | MEVPRO-1 mCRPC after abiraterone: mevrometostat + enzalutamide vs physician's choice (enzalutamide or docetaxel) | Phase 3 | Recruiting | — | 600 | 49 Emerging |
| 334 | SOHO-01 HER2-mutant NSCLC, previously treated and treatment-naive: sevabertinib single arm | Phase 1/2 | Positive | Objective response rate, HER2-mutant NSCLC after platinum (Cohort D): 70.5% | 407 | 49 Emerging |
| 335 | TeliMET NSCLC-01 Previously treated c-Met-overexpressing, EGFR-wild-type non-squamous NSCLC: telisotuzumab vedotin vs docetaxel | Phase 3 | Recruiting | — | 698 | 49 Emerging |
| 336 | TROPION-Breast05 First-line PD-L1+ metastatic TNBC: Dato-DXd ± durvalumab vs pembrolizumab + chemotherapy | Phase 3 | Recruiting | — | 625 | 49 Emerging |
| 337 | XALute mCRPC after ARPI and taxane: xaluritamig vs cabazitaxel or second ARPI (investigator's choice; ≥50% cabazitaxel) | Phase 3 | Active | — | 675 | 49 Emerging |
| 338 | ASPREE (ASPirin in Reducing Events in the Elderly) Community-dwelling adults aged 70+ (65+ for US Black and Hispanic participants) without cardiovascular disease, dementia or disability: aspirin 100 mg/day vs placebo | Phase 3 | Negative | Death from cancer: 295 events vs 227 events, HR 1.31 | 19,114 | 48 Emerging |
| 339 | GD2-CART01 (Bambino Gesù phase 1/2) Relapsed/refractory high-risk neuroblastoma: third-generation GD2 CAR-T with inducible caspase-9 safety switch | Phase 1/2 | Positive | Objective response rate: 63% | 27 | 48 Emerging |
| 340 | iMMagine-1 Relapsed/refractory myeloma after ≥4 lines: anito-cel single infusion | Phase 2 | Positive | Objective response rate: 97% | 117 | 48 Emerging |
| 341 | LACC (Laparoscopic Approach to Cervical Cancer) Early-stage cervical cancer (IA1 with LVSI to IB1): minimally invasive vs open radical hysterectomy | Phase 3 | Negative | Disease-free survival at 4.5 years: 86% vs 96.5%, HR 3.74 | 631 | 48 Emerging |
| 342 | MonumenTAL-1 Relapsed/refractory myeloma after ≥3 lines: talquetamab (weekly or biweekly) | Phase 1/2 | Positive | Objective response rate: 71.7% vs 74.1% | 288 | 48 Emerging |
| 343 | PATHFINDER 2 ~35,000 adults ≥50 receiving Galleri alongside standard screening, single-arm | Phase observational | Completed | Cancer signal detected: 0.93% | 35,878 | 48 Emerging |
| 344 | TrilynX Unresected locally advanced HNSCC: xevinapant + cisplatin chemoradiation vs placebo + chemoradiation | Phase 3 | Negative | Event-free survival: 19.4 months vs 33.1 months | 730 | 48 Emerging |
| 345 | VITAL (VITamin D and OmegA-3 TriaL) Primary prevention in US adults (men 50+, women 55+) without prior cancer or cardiovascular disease: vitamin D3 2000 IU/day and/or marine omega-3 1 g/day vs placebo, 2x2 factorial | Phase 3 | Negative | Invasive cancer of any type: 793 events vs 824 events, HR 0.96 | 25,871 | 48 Emerging |
| 346 | BELINDA Early-relapsed/refractory aggressive B-cell lymphoma: tisagenlecleucel vs salvage + transplant | Phase 3 | Negative | Event-free survival (median): 3 months vs 3 months, HR 1.07 | 322 | 47 Emerging |
| 347 | IGNYTE-ESO Advanced synovial sarcoma or myxoid/round cell liposarcoma, NY-ESO-1+, HLA-A*02+: lete-cel (single arm) | Phase 2 | Positive | Objective response rate: 42% | 64 | 47 Emerging |
| 348 | MajesTEC-1 Relapsed/refractory myeloma after ≥3 lines: teclistamab monotherapy | Phase 1/2 | Positive | Objective response rate: 63% | 165 | 47 Emerging |
| 349 | ARROW (thyroid cohorts) RET-mutant medullary and RET-fusion thyroid cancer: pralsetinib | Phase 1/2 | Positive | Objective response rate, treatment-naive RET-mutant MTC: 71% | — | 46 Emerging |
| 350 | CARTITUDE-1 Relapsed/refractory myeloma after ≥3 lines, triple-class exposed: cilta-cel single infusion | Phase 1/2 | Positive | Objective response rate: 97.9% | 97 | 46 Emerging |
| 351 | LINKER-MM1 Relapsed/refractory myeloma after ≥3 lines: linvoseltamab 200 mg | Phase 1/2 | Positive | Objective response rate: 70% | 117 | 46 Emerging |
| 352 | CIRCULATE-Japan (GALAXY / VEGA / ALTAIR) Resected stage II-IV colorectal cancer: ctDNA (Signatera) to guide adjuvant chemotherapy de-escalation (VEGA) or escalation with trifluridine/tipiracil (ALTAIR) | Phase 3 | Active | — | — | 45 Emerging |
| 353 | ACT IV Newly diagnosed EGFRvIII+ glioblastoma with minimal residual disease: rindopepimut + temozolomide vs control (KLH) + temozolomide | Phase 3 | Negative | Overall survival, minimal residual disease population: 20.1 months vs 20 months, HR 1.01 | 745 | 44 Emerging |
| 354 | ALKOVE-1 ALK-positive NSCLC after prior ALK TKIs (including lorlatinib): neladalkib single arm | Phase 1/2 | Positive | Objective response rate, TKI-pretreated ALK+ NSCLC (pivotal cohort): 51% | 432 | 44 Emerging |
| 355 | AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617) PSMA-positive mCRPC: actinium-225 PSMA radioligands vs standard of care, including after 177Lu-PSMA | Phase 3 | Recruiting | — | 600 | 44 Emerging |
| 356 | FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh) Metastatic melanoma with primary resistance to anti-PD-1: single colonoscopic FMT from a durable responder donor, then pembrolizumab | Phase 2 | Completed | Clinical benefit (objective response or SD over 12 months): 40% | 15 | 44 Emerging |
| 357 | IZABRIGHT-Breast01 First-line metastatic TNBC ineligible for PD-(L)1 inhibitors: iza-bren vs chemotherapy | Phase 3 | Recruiting | — | 570 | 44 Emerging |
| 358 | IMpassion131 First-line metastatic TNBC: atezolizumab + paclitaxel vs paclitaxel | Phase 3 | Negative | Progression-free survival, PD-L1+ (investigator): 6 months vs 5.7 months, HR 0.82 | 651 | 43 Emerging |
| 359 | MOUNTAINEER & MOUNTAINEER-03 HER2-positive RAS wild-type metastatic colorectal cancer: tucatinib + trastuzumab (phase 2, pretreated); tucatinib + trastuzumab + mFOLFOX6 vs standard first line (phase 3) | Phase 3 | Recruiting | Objective response rate (phase 2): 38.1 percent | — | 43 Emerging |
| 360 | QUILT 3.032 BCG-unresponsive NMIBC with CIS: nogapendekin alfa inbakicept (N-803) + BCG, single arm | Phase 2 | Positive | Complete response rate (CIS): 71% | — | 43 Emerging |
| 361 | RAMP 201 Recurrent low-grade serous ovarian cancer: avutometinib (RAF/MEK clamp) + defactinib (FAK inhibitor) | Phase 2 | Positive | Objective response rate (KRAS-mutant): 44% | — | 43 Emerging |
| 362 | SunRISe-1 BCG-unresponsive high-risk NMIBC with carcinoma in situ: TAR-200 (gemcitabine intravesical system) ± cetrelimab, single-arm cohorts | Phase 2 | Positive | Complete response rate (CIS): 82% | — | 43 Emerging |
| 363 | LUME-Meso Epithelioid pleural mesothelioma, first line: cisplatin-pemetrexed ± nintedanib | Phase 3 | Negative | Progression-free survival: 6.8 months vs 7 months, HR 1.01 | 458 | 42 Emerging |
| 364 | VOYAGER Third/fourth-line GIST: avapritinib vs regorafenib | Phase 3 | Negative | Progression-free survival (median): 4.2 months vs 5.6 months, HR 1.25 | 476 | 42 Emerging |
| 365 | ASTRA High-risk differentiated thyroid cancer: selumetinib + adjuvant radioiodine vs placebo + radioiodine | Phase 3 | Negative | Complete remission at 18 months: 40% vs 38.5% | 401 | 41 Emerging |
| 366 | ALPHAMEDIX-02 Unresectable or metastatic SSTR-positive GEP-NETs, PRRT-naive and PRRT-exposed cohorts: 212Pb-DOTAMTATE single arm | Phase 2 | Positive | Objective response rate (PRRT-naive): 54.3% | — | 38 Emerging |
| 367 | NRG-HN002 & NRG-HN005 (HPV+ de-escalation) Low-risk HPV-positive oropharyngeal cancer: reduced-dose radiation (60 Gy) with or without cisplatin, or with nivolumab, vs standard 70 Gy chemoradiation | Phase 2/3 | Mixed | — | — | 38 Emerging |
| 368 | UKCTOCS Postmenopausal women aged 50-74: annual multimodal (CA-125 algorithm + ultrasound) or ultrasound screening vs no screening | Phase 3 | Negative | Ovarian and tubal cancer mortality reduction (multimodal vs none): 4% | 202,638 | 38 Emerging |
| 369 | ACTION-1 SSTR-positive GEP-NETs progressing after 177Lu somatostatin-analogue therapy: 225Ac-DOTATATE (RYZ101) vs investigator's choice | Phase 3 | Recruiting | — | — | 35 Emerging |
| 370 | AHOD2131 (COG / NCTN) Newly diagnosed stage I-II classical Hodgkin lymphoma, age 5-60: standard therapy vs brentuximab vedotin + nivolumab (response-adapted), with or without radiation | Phase 3 | Recruiting | — | — | 35 Emerging |
| 371 | BELLWAVE-011 Previously untreated CLL/SLL: nemtabrutinib vs investigator's choice of ibrutinib or acalabrutinib | Phase 3 | Recruiting | — | — | 35 Emerging |
| 372 | CaDAnCe-304 Relapsed/refractory CLL/SLL after a covalent BTK inhibitor: BTK degrader BGB-16673 vs pirtobrutinib | Phase 3 | Recruiting | — | — | 35 Emerging |
| 373 | CARTITUDE-5 Newly diagnosed myeloma, transplant not planned: VRd → cilta-cel vs VRd → Rd | Phase 3 | Recruiting | — | — | 35 Emerging |
| 374 | CELESTIAL-TNCLL Previously untreated CLL/SLL: fixed-duration sonrotoclax + zanubrutinib vs venetoclax + obinutuzumab | Phase 3 | Active | — | — | 35 Emerging |
| 375 | COG ANBL1531 Newly diagnosed high-risk neuroblastoma: 131I-MIBG added to induction (randomised, MIBG-avid); lorlatinib added for ALK-aberrant tumours (non-randomised arm) | Phase 3 | Active | — | — | 35 Emerging |
| 376 | EPCORE DLBCL-2 Untreated DLBCL: epcoritamab + R-CHOP vs R-CHOP | Phase 3 | Active | — | — | 35 Emerging |
| 377 | HERIZON-BTC-302 First-line HER2-positive advanced biliary tract cancer: zanidatamab + standard of care (GemCis ± PD-1) vs standard of care | Phase 3 | Recruiting | — | — | 35 Emerging |
| 378 | IDeate-Lung02 Relapsed SCLC after one prior line: ifinatamab deruxtecan vs topotecan, amrubicin, or lurbinectedin | Phase 3 | Recruiting | — | — | 35 Emerging |
| 379 | LiGeR-HN1 Untreated PD-L1-positive recurrent or metastatic HNSCC: petosemtamab + pembrolizumab vs pembrolizumab | Phase 3 | Recruiting | — | — | 35 Emerging |
| 380 | PRISM-MEL-301 Untreated HLA-A*02:01-positive advanced cutaneous melanoma: brenetafusp + nivolumab vs nivolumab-based regimens | Phase 3 | Recruiting | — | — | 35 Emerging |
| 381 | SARAH and SIRveNIB Locally advanced HCC: yttrium-90 radioembolisation vs sorafenib | Phase 3 | Negative | Overall survival (SARAH): 8 months vs 9.9 months, HR 1.15 | — | 35 Emerging |
| 382 | JAVELIN Head and Neck 100 Locally advanced HNSCC: avelumab + chemoradiation then avelumab maintenance vs chemoradiation | Phase 3 | Negative | — | 697 | 34 Emerging |
| 383 | MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma Untreated advanced melanoma: oral capsule FMT from healthy donors one week before, then with, nivolumab or pembrolizumab | Phase 1 | Completed | Objective response rate: 65% | 20 | 34 Emerging |
| 384 | FIRST-308 FGFR-altered cholangiocarcinoma refractory to chemotherapy and a first-generation FGFR inhibitor: tinengotinib vs FOLFOX/FOLFIRI | Phase 3 | Recruiting | — | — | 30 Emerging |
| 385 | GOLSEEK-1 Untreated high-risk LBCL (IPI 3-5): golcadomide + R-CHOP vs placebo + R-CHOP | Phase 3 | Recruiting | — | — | 30 Emerging |
| 386 | iStopMM Population screening of Icelanders over 40 for MGUS with randomised follow-up strategies | Phase observational | Active | — | 75,000 | 30 Emerging |
| 387 | REJOICE-Ovarian01 Platinum-resistant ovarian cancer, 1-3 prior lines: raludotatug deruxtecan (CDH6 ADC) vs physician's-choice chemotherapy | Phase 2/3 | Recruiting | Objective response rate (phase 2 part): 50.5% | — | 30 Emerging |
| 388 | SENTICOL III Early-stage cervical cancer: sentinel lymph node biopsy alone vs sentinel node plus full pelvic lymphadenectomy | Phase 3 | Recruiting | — | — | 30 Emerging |
| 389 | waveLINE-003 R/R DLBCL after ≥1 line: zilovertamab vedotin + R-GemOx vs R-GemOx | Phase 3 | Recruiting | — | — | 30 Emerging |
| 390 | XPORT-EC-042 / ENGOT-EN20 / GOG-3083 TP53-wild-type advanced or recurrent endometrial cancer after response to platinum: maintenance selinexor vs placebo | Phase 3 | Negative | Progression-free survival (mITT): 12.75 months vs 7.43 months | — | 29 Preliminary |
| 391 | FORTIFI-HN01 Untreated PD-L1-positive, HPV-negative recurrent or metastatic HNSCC: ficerafusp alfa + pembrolizumab vs pembrolizumab | Phase 2/3 | Recruiting | — | — | 27 Preliminary |
| 392 | FIRES & SENTOR (sentinel node mapping) Endometrial cancer staging: indocyanine-green sentinel lymph node mapping compared against full lymphadenectomy | Phase observational | Positive | — | — | 25 Preliminary |
| 393 | NALIRICC (AIO) Second-line biliary tract cancer after gemcitabine: liposomal irinotecan + 5-FU/LV vs 5-FU/LV | Phase 2 | Negative | Overall survival: 6.9 months vs 8.2 months | 100 | 25 Preliminary |
| 394 | ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma Recurrent glioblastoma and other malignant gliomas undergoing re-irradiation: 6-day calorie-restricted ketogenic diet plus 3-day fasting during radiotherapy vs standard diet | Phase 2 | Negative | Progression-free survival at 6 months: 20% vs 16% | 50 | 17 Preliminary |
| 395 | AMPLIFY-7P Adjuvant mKRAS PDAC after surgery and chemotherapy: ELI-002 7P vs observation | Phase 2 | Negative | — | 144 | 16 Preliminary |
| 396 | RAINFOL-01 (Rina-S) Advanced ovarian and endometrial cancer, heavily pretreated: rinatabart sesutecan (FRα ADC, exatecan payload) across FRα expression levels | Phase 1/2 | Active | Objective response rate, ovarian, 120 mg/m²: 55.6% | — | 16 Preliminary |
| 397 | DREAM3R Unresectable pleural mesothelioma, first line: durvalumab + platinum-pemetrexed vs chemotherapy | Phase 3 | Negative | — | — | 15 Preliminary |
| 398 | Fianlimab + cemiplimab phase 3 (first-line melanoma) Untreated unresectable or metastatic melanoma: fianlimab + cemiplimab (two dose levels) vs pembrolizumab | Phase 3 | Negative | — | — | 15 Preliminary |
| 399 | LITESPARK-012 Untreated advanced clear-cell RCC: pembrolizumab + lenvatinib ± belzutifan (or ± quavonlimab) | Phase 3 | Negative | — | — | 15 Preliminary |
| 400 | myeloMATCH Newly diagnosed AML and MDS: genomic screening at diagnosis assigns patients to tiered, biomarker-defined sub-studies from induction through MRD-guided consolidation and maintenance | Phase platform | Recruiting | — | — | 15 Preliminary |
| 401 | RELATIVITY-098 Resected stage III/IV melanoma: adjuvant nivolumab + relatlimab vs nivolumab | Phase 3 | Negative | — | — | 15 Preliminary |